About   Help   FAQ
Mammalian Phenotype Ontology Annotations
Query Results - Summary
4278 genotypes with 8399 annotations displayed of selected term and subterms
Searched Term: neoplasm
Allelic Composition
(Genetic Background)
Annotated Term Reference
A4gnttm1Jnaka/A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka)
increased gastric adenocarcinoma incidence J:184485
increased tumor growth/size J:184485
Avy/?
(129S1.C3-Avy)
neoplasm J:146879
Avy/a
(involves: C3H/HeJ * C57BL/6)
increased tumor incidence J:117156
Avy/Aw
(129S1.C3-Avy/Aw Chr 19MOLF/Ei)
neoplasm J:146879
Ay/Aw
(129S1.C3-Ay/Aw Chr 19MOLF/Ei)
decreased incidence of induced tumors J:146879
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
increased hepatocellular carcinoma incidence J:21232
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
increased hepatocellular carcinoma incidence J:217802
Abcb4tm1Bor/Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor)
increased hepatocellular carcinoma incidence J:217802
Abi3bptm1.1Smoc/Abi3bptm1.1Smoc
(B6.129S6(FVB)-Abi3bptm1.1Smoc)
neoplasm J:278622
Abraxas1tm1.1Bwng/Abraxas1+
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
increased histiocytic sarcoma incidence J:269823
increased lung adenocarcinoma incidence J:269823
increased lymphoma incidence J:269823
increased tumor incidence J:269823
Abraxas1tm1.1Bwng/Abraxas1tm1.1Bwng
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
increased lymphoma incidence J:269823
increased tumor incidence J:269823
Acadvltm1Vje/Acadvltm1Vje
(involves: 129/Sv * C57BL/6)
increased tumor incidence J:102010
Acdtm1.1Blas/Acdtm1.1Blas
Tg(KRT5-cre)1Tak/?

(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6 * SJL)
preneoplasia J:160600
Acetm6Keb/Ace+
(involves: 129 * C57BL/6)
decreased tumor growth/size J:122178
Acetm6Keb/Acetm6Keb
(involves: 129 * C57BL/6)
abnormal tumor morphology J:122178
decreased tumor growth/size J:122178
Acetm6Keb/Acetm6Keb
(involves: 129 * C57BL/6 * CD-1)
decreased tumor growth/size J:122178
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J)
increased hepatocellular carcinoma incidence J:174942
Acox1tm1Jkr/Acox1tm1Jkr
(involves: 129P2/OlaHsd * C57BL/6J)
increased hepatocellular carcinoma incidence J:35794
increased hepatoma incidence J:48180
Acpptm1Pivi/Acpptm1Pivi
(B6.Cg-Acpptm1Pivi)
increased prostate gland adenocarcinoma incidence J:207558
increased prostate intraepithelial neoplasia incidence J:207558
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv)
increased hemangioma incidence J:87544
increased mammary adenocarcinoma incidence J:87544
Actbtm1(PyVT)Arge/Actb+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv)
increased mammary adenocarcinoma incidence J:87544
Actbtm1(Tag)Arge/Actb+
(involves: 129S1/Sv)
increased sarcoma incidence J:87544
Actbtm1(Tag)Arge/Actb+
Tg(Hsp70-1-cre)1Arge/0

(involves: 129S1/Sv * C57BL/6J * CBA)
increased leiomyosarcoma incidence J:87544
Actn4tm1a(EUCOMM)Wtsi/Actn4tm1a(EUCOMM)Wtsi
(C57BL/6N-Actn4tm1a(EUCOMM)Wtsi/Wtsi)
embryo tumor J:239583
Acvr1tm1Emsh/Acvr1+
(chimera involves: BALB/c * C57BL/6 * CD-1)
increased osteochondroma incidence J:194134
Adam9tm1Bbl/Adam9tm1Bbl
(involves: 129)
decreased tumor growth/size J:148993
Adam15tm1Bbl/Adam15tm1Bbl
(involves: 129X1/SvJ * C57BL/6J)
altered tumor susceptibility J:84800, J:217858
decreased tumor growth/size J:217858
decreased tumor incidence J:217858
Adam15tm1Bbl/Adam15tm1Bbl
(B6.129X1-Adam15tm1Bbl)
decreased tumor growth/size J:84800
Adam15tm2.1Bbl/Adam15tm2.1Bbl
(involves: 129/SvJ * 129P2/OlaHsd * C57BL/6J * SJL)
altered tumor susceptibility J:217858
decreased tumor growth/size J:217858
decreased tumor incidence J:217858
Adamts12tm1Agno/Adamts12tm1Agno
(Not Specified)
abnormal tumor vascularization J:160778
increased tumor growth/size J:160778
Adamts18tm1.1Wzha/Adamts18tm1.1Wzha
(involves: 129 * C57BL/6)
increased incidence of tumors by chemical induction J:258487
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0

(B6.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
abnormal tumor morphology J:147458
increased mammary gland tumor incidence J:147458
increased metastatic potential J:147458
increased tumor growth/size J:147458
Adipoqtm1Chan/Adipoq+
Tg(MMTV-PyVT)634Mul/0

(FVB.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
abnormal tumor morphology J:147458
increased mammary gland tumor incidence J:147458
increased metastatic potential J:147458
increased tumor growth/size J:147458
Afptm1(Cebpa)Ndw/Afp+
(involves: 129S7/SvEvBrd)
decreased incidence of tumors by chemical induction J:103404
Aggf1Gt(PT036)Byg/Aggf1+
(involves: 129P2/OlaHsd * C57BL/6)
abnormal tumor vascularization J:239252
decreased tumor incidence J:239252
Aggf1tm1Qkw/Aggf1+
(involves: 129 * C57BL/6)
abnormal tumor vascularization J:239252
decreased tumor incidence J:239252
Agtr2tm1Tin/Y
(SWR.129P2-Agtr2tm1Tin)
decreased incidence of tumors by chemical induction J:101726
Ahrb-1/Ahrd
(involves: 129S1/SvImJ * C57BL/6J)
increased incidence of tumors by chemical induction J:113356
Ahrd/Ahrd
(involves: 129S1/SvImJ * C57BL/6J)
increased incidence of tumors by chemical induction J:113356
Ahrtm1Bra/Ahr+
Tg(TRAMP)8247Ng/0

(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
increased prostate gland tumor incidence J:118152
Ahrtm1Bra/Ahrtm1Bra
Tg(TRAMP)8247Ng/0

(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
increased prostate gland tumor incidence J:118152
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N)
increased hepatoma incidence J:44690
increased liver adenoma incidence J:44690
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
increased urinary bladder carcinoma incidence J:179919
Ahrrtm1Yfk/Ahrrtm1Yfk
(involves: 129P2/OlaHsd * C57BL/6)
decreased incidence of tumors by chemical induction J:130214
Aicdatm1(cre)Mnz/Aicda+
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+
TgTn(sb-T2/Onc2)6070Njen/0

(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
increased B cell derived lymphoma incidence J:153656
increased follicular lymphoma incidence J:153656
increased hemolymphoid system tumor incidence J:153656
increased leukemia incidence J:153656
increased medulloblastoma incidence J:153656
increased skin squamous cell carcinoma incidence J:153656
increased T cell derived lymphoma incidence J:153656
increased tumor incidence J:153656
Aifm2tm1Hbsh/Aifm2tm1Hbsh
(involves: 129S6/SvEvTac)
neoplasm J:105660
AipGt(RRI002)Byg/Aip+
(involves: 129P2/OlaHsd * C57BL/6)
increased pituitary adenoma incidence J:165349
increased prolactinoma incidence J:165349
Airetm1Pltn/Airetm1Pltn
(B6.129S4-Airetm1Pltn)
increased B cell derived lymphoma incidence J:115076
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt1Gt1Pnt/Akt1Gt1Pnt
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Ptentm1Hwu/Ptentm1Hwu
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
increased tumor latency J:218587
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt2tm1.1Mbb/Akt2tm1.1Mbb
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Akt3tm1Mbb/Akt3tm1Mbb
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:117336
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
(C57BL/6N-Aktiptm1a(EUCOMM)Hmgu)
neoplasm J:276210
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * C57BL/6N)
increased lymphoma incidence J:276210
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas * C57BL/6N)
increased lymphoma incidence J:276210
Albtm1(cre/ERT2)Mtz/Alb+
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+

(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6)
increased cholangiocarcinoma incidence J:192740
Albtm1(cre/ERT2)Mtz/Alb+
Hes1tm1Kag/Hes1tm1Kag

(involves: 129S2/SvPas * C57BL/6 * CBA)
neoplasm J:192740
Albtm1(cre/ERT2)Mtz/Alb+
Krastm4Tyj/Kras+
Ptentm2Mak/Ptentm2Mak

(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae)
increased cholangiocarcinoma incidence J:254370
increased hepatocellular carcinoma incidence J:254370
Aldh2tm1.1Mak/Aldh2+
(involves: 129S6/SvEvTac * C57BL/6J)
increased incidence of tumors by chemical induction J:223796
Aldh2tm1.1Mak/Aldh2tm1.1Mak
(involves: 129S6/SvEvTac * C57BL/6J)
decreased tumor latency J:223796
increased incidence of tumors by chemical induction J:223796
Aldh2tm1a(EUCOMM)Wtsi/Aldh2tm1a(EUCOMM)Wtsi
Fancd2tm1Hou/Fancd2tm1Hou

(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
increased acute lymphoblastic leukemia incidence J:193232
increased lymphoma incidence J:193232
increased T cell derived lymphoma incidence J:193232
Alktm1.1Ics/?
Tg(Th-MYCN)41Waw/0

(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
increased neuroblastoma incidence J:228124, J:261033
Alktm2.1Ics/?
Tg(Th-MYCN)41Waw/0

(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
increased neuroblastoma incidence J:228124, J:261033
Alox15tm1Fun/Alox15tm1Fun
(B6.129S2-Alox15tm1Fun/J)
increased chronic myelocytic leukemia incidence J:119405
Ambntm1Nid/Ambntm1Nid
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased tumor incidence J:94844
Amelxtm1Kul/Amelxtm1Kul
Tg(AMELX*P70T)2Gibs/?

(involves: 129S1/Sv * 129X1/SvJ)
increased tumor incidence J:122914
AmfrGt(IST12797A11)Tigm/AmfrGt(IST12797A11)Tigm
(C57BL/6-AmfrGt(IST12797A11)Tigm)
increased liver tumor incidence J:221247
Amhtm1Bhr/Amh+
Amhr2tm1Bhr/Amhr2tm1Bhr

(involves: 129S7/SvEvBrd * C57BL/6)
increased testis tumor incidence J:36027
Amhr2tm1Bhr/Amhr2tm1Bhr
Inhatm1Bay/Inha+

(involves: 129S7/SvEvBrd * C57BL/6)
increased testis tumor incidence J:36027
Amhr2tm1Bhr/Amhr2tm1Bhr
Inhatm1Bay/Inhatm1Bay

(involves: 129S7/SvEvBrd)
increased granulosa cell tumor incidence J:36027
increased Leydig cell tumor incidence J:36027
increased testis tumor incidence J:36027
increased tumor incidence J:36027
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
increased testis tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+

(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased testis tumor incidence J:186144
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ)
increased granulosa cell tumor incidence J:149060
increased metastatic potential J:142150, J:149060
increased ovary tumor incidence J:142150
increased testis tumor incidence J:149060
Amhr2tm3(cre)Bhr/Amhr2+
Ctnnb1tm1Mmt/Ctnnb1+
Ptentm1Hwu/Ptentm1Hwu

(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
increased granulosa cell tumor incidence J:186144
increased testis tumor incidence J:186144
Amhr2tm3(cre)Bhr/Amhr2+
KitW-v/KitW-v
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N)
increased granulosa cell tumor incidence J:236161
increased ovary adenoma incidence J:236161
increased ovary tumor incidence J:236161
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
increased testis tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2.1Rob
Smad5tm1Huy/Smad5tm1Huy

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased granulosa cell tumor incidence J:157310
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Huy

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased granulosa cell tumor incidence J:157310
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk

(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
increased testis tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk

(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
increased granulosa cell tumor incidence J:157310
Amhr2tm3(cre)Bhr/Amhr2+
Smad1tm2Rob/Smad1tm2Rob
Smad5tm1Huy/Smad5tm1Zuk
Smad9tm1Jfm/Smad9tm1Jfm

(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
increased ovarian carcinoma incidence J:128934
increased ovary tumor incidence J:128934
Amhr2tm3(cre)Bhr/Amhr2+
Stk11tm1Rdp/Stk11tm1Rdp

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
neoplasm J:187754
Amhr2tm3(cre)Bhr/Amhr2+
Trp53tm2Tyj/Trp53+

(involves: 129S4/SvJae * 129S7/SvEvBrd)
neoplasm J:222579
Amhr2tm3(cre)Bhr/Amhr2+
Tsc1tm1Djk/Tsc1tm1Djk

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
neoplasm J:187754
Amhr2tm3(cre)Bhr/Amhr2+
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
neoplasm J:187754
Anp32btm1Mak/Anp32btm1Mak
(C.129P2(B6)-Anp32btm1Mak)
increased incidence of tumors by chemical induction J:227403
Antxr1tm1.2Bstc/Antxr1tm1.2Bstc
(B6.Cg-Antxr1tm1.2Bstc)
decreased tumor growth/size J:150947
Anxa1tm1Rjf/Anxa1tm1Rjf
(involves: 129 * C57BL/6)
abnormal tumor vascularization J:153690
decreased metastatic potential J:153690
decreased tumor growth/size J:153690
Anxa1tm1Rjf/Anxa1tm1Rjf
Tg(MMTV-PyVT)634Mul/?

(involves: FVB/N)
decreased metastatic potential J:174635
decreased tumor growth/size J:174635
Anxa7tm1Pll/Anxa7+
(B6.Cg-Anxa7tm1Pll)
increased hepatocellular carcinoma incidence J:93685
increased lymphoma incidence J:93685
increased tumor incidence J:93685
Apaf1tm1Her/Apaf1tm1Her
(involves: 129S6/SvEvTac * C57BL/6J)
neoplasm J:60409
ApcGt(XA018)Byg/Apc+
(B6.129P2-ApcGt(XA018)Byg)
increased colon adenoma incidence J:202877
increased intestinal adenoma incidence J:202877
increased tumor growth/size J:202877
ApcGt(XA018)Byg/Apc+
((B6.129P2-ApcGt(XA018)Byg x C3H/HeJ)F1)
decreased tumor growth/size J:202877
ApcM1Tno/Apc+
(involves: C57BL/6 * DBA/2JJcl)
increased mammary gland tumor incidence J:218227
increased osteoma incidence J:218227
increased skin tumor incidence J:218227
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl))
increased mammary adenocarcinoma incidence J:218227
increased mammary gland tumor incidence J:218227
increased osteoma incidence J:218227
increased osteosarcoma incidence J:218227
increased pilomatricoma incidence J:218227
increased skin tumor incidence J:218227
increased trichoepithelioma incidence J:218227
ApcMin/Apc+
(involves: AKR/J * C57BL/6J)
increased intestinal adenocarcinoma incidence J:10209
increased intestinal adenoma incidence J:10209
ApcMin/Apc+
(C57BL/6J-ApcMin)
increased colon adenoma incidence J:160399, J:158733
increased intestinal adenoma incidence J:85142, J:241611, J:1879, J:158733
ApcMin/Apc+
(involves: C57BL/6J)
increased intestinal adenoma incidence J:75393, J:94108
increased mammary adenocarcinoma incidence J:94108
ApcMin/Apc+
(B6.Cg-Brca2tm1Mbn ApcMin)
increased incidence of induced tumors J:67445
increased mammary gland tumor incidence J:67445
ApcMin/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
increased intestinal adenoma incidence J:95893
neoplasm J:95893
ApcMin/Apc+
(B6(AKR)-ApcMin)
increased intestinal adenocarcinoma incidence J:10209
increased intestinal adenoma incidence J:10209
increased mammary gland tumor incidence J:15101
ApcMin/Apc+
((AKR/J x C57BL/6J-ApcMin)F1)
decreased intestinal adenoma incidence J:1879
increased incidence of tumors by chemical induction J:15101
increased intestinal adenocarcinoma incidence J:21369
ApcMin/Apc+
((MA/MyJ x C57BL/6J-ApcMin)F1)
decreased intestinal adenoma incidence J:1879
ApcMin/Apc+
Arhgef4tm1Taki/Arhgef4+

(B6J.Cg-Arhgef4tm1Taki ApcMin)
decreased intestinal adenoma incidence J:157023
decreased tumor growth/size J:157023
ApcMin/Apc+
Arhgef4tm1Taki/Arhgef4tm1Taki

(B6J.Cg-Arhgef4tm1Taki ApcMin)
decreased intestinal adenoma incidence J:157023
decreased tumor growth/size J:157023
ApcMin/Apc+
Arhgef4tm1Taki/Arhgef4tm1Taki
Spata13tm1Taki/Spata13tm1Taki

(B6J.Cg-Arhgef4tm1Taki Spata13tm1Taki ApcMin)
abnormal tumor vascularization J:157023
altered tumor pathology J:157023
decreased intestinal adenoma incidence J:157023
decreased tumor growth/size J:157023
ApcMin/Apc+
Atp5a1Mom2/Atp5a1+

(involves: C57BL/6J * DBA/2J)
decreased tumor incidence J:73854
ApcMin/Apc+
Atp5a1Mom2/Atp5a1Mom2

(involves: C57BL/6J * DBA/2J)
decreased tumor incidence J:73854
ApcMin/Apc+
Blmtm1Grdn/Blm+

(involves: 129P2/OlaHsd * 129S/SvEv * Black Swiss * C57BL/6J)
increased colon adenoma incidence J:79058
increased gastrointestinal tumor incidence J:79058
increased intestinal adenoma incidence J:79058
ApcMin/Apc+
Brca2tm1Mbn/Brca2+

(B6.Cg-Brca2tm1Mbn ApcMin)
increased incidence of induced tumors J:67445
increased incidence of tumors by chemical induction J:67445
increased mammary gland tumor incidence J:67445
ApcMin/Apc+
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk

(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * C57BL/6J * C57BL/6N)
increased colon adenocarcinoma incidence J:216704
increased colon adenoma incidence J:216704
increased colon tumor incidence J:216704
increased gastrointestinal tumor incidence J:216704
ApcMin/Apc+
Ccnd1tm1Dsn/Ccnd1tm1Dsn

(involves: C57BL/6J)
increased intestinal adenoma incidence J:78500
ApcMin/Apc+
Cd44tm1Mak/Cd44tm1Mak

(involves: 129P2/OlaHsd * C57BL/6J)
decreased intestinal adenoma incidence J:135025
ApcMin/Apc+
Cd44tm1Mak/Cd44tm1Mak

(involves: C57BL/6J)
decreased intestinal adenoma incidence J:204874
ApcMin/Apc+
Cd44tm1Stpa/Cd44tm1Stpa

(involves: C57BL/6J * C57BL/6JIco)
increased intestinal adenoma incidence J:204874
ApcMin/Apc+
Cd44tm1Stpa/Cd44tm2Stpa

(involves: C57BL/6J)
increased intestinal adenoma incidence J:204874
ApcMin/Apc+
Cd44tm2Stpa/Cd44tm2Stpa

(involves: C57BL/6J)
decreased intestinal adenoma incidence J:204874
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
increased gastrointestinal tumor incidence J:134301
ApcMin/Apc+
Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
Tg(Vil1-cre)997Gum/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL)
decreased tumor incidence J:134301
ApcMin/Apc+
Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
increased intestinal adenoma incidence J:127808
increased tumor growth/size J:127808
ApcMin/Apc+
Col1a1tm10(tetO-Dnmt3b_i3)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
neoplasm J:127808
ApcMin/Apc+
Col1a1tm11(tetO-Dnmt3b_i6)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
neoplasm J:127808
ApcMin/Apc+
Col1a1tm12(tetO-Dnmt3a_i1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
neoplasm J:127808
ApcMin/Apc+
Dcctm1Wbg/Dcc+

(involves: C57BL/6J)
increased intestinal adenoma incidence J:39765
ApcMin/Apc+
Dclk1tm1.1(cre/ERT2)Seno/Dclk1+
Gt(ROSA)26Sortm1(HBEGF)Awai/Gt(ROSA)26Sor+
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+

(involves: 129S4/SvJaeSor * C57BL/6)
abnormal tumor morphology J:193873
ApcMin/Apc+
Dnd1Ter/Dnd1+

(involves: 129P3/J * C57BL/6J)
increased intestinal adenoma incidence J:221231
ApcMin/Apc+
Dnmt3btm1Jae/Dnmt3btm1Jae
Tg(Fabp1-cre)1Jig/0

(involves: 129 * C57BL/6 * C57BL/6J * FVB/N)
decreased tumor incidence J:107386
ApcMin/Apc+
Dp(17Nfkbil1-Olfr91)1Cogr/0

(involves: 129S6/SvEvTac * C57BL/6J)
neoplasm J:190754
ApcMin/Apc+
EgfrWa5/Egfr+

(involves: BALB/cAnN * C3H/HeN * C57BL/6J)
decreased tumor incidence J:92308
ApcMin/Apc+
Elp3tm1.1Tac/Elp3tm1.1Tac
Tg(Vil1-cre)997Gum/0

(involves: C57BL/6 * C57BL/6J * C57BL/6NTac * SJL)
decreased intestinal adenoma incidence J:227334
increased tumor latency J:227334
ApcMin/Apc+
Erbb3tm1.1Dwt/Erbb3tm2.1Dwt
Tg(Vil1-cre)997Gum/0

(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
decreased tumor incidence J:152703
ApcMin/Apc+
Eregtm1Dwt/Eregtm1Dwt

(involves: 129S6/SvEvTac * C57BL/6J)
increased intestinal adenoma incidence J:93327
ApcMin/Apc+
Esr1tm1.1Mma/Esr1+

(involves: 129S2/SvPas * C57BL/6J)
increased carcinoma incidence J:118600
increased colon adenoma incidence J:118600
increased gastrointestinal tumor incidence J:118600
ApcMin/Apc+
Esr2tm1Mma/Esr2+

(involves: 129S2/SvPas * C57BL/6J)
increased gastrointestinal tumor incidence J:118600
ApcMin/Apc+
Esr2tm1Mma/Esr2tm1Mma

(involves: 129S2/SvPas * C57BL/6J)
increased colon adenoma incidence J:118600
increased gastrointestinal tumor incidence J:118600
ApcMin/Apc+
Foxl1tm1Khk/Foxl1tm1Khk

(involves: 129P2/OlaHsd * C57BL/6)
increased colon adenoma incidence J:95893
neoplasm J:95893
ApcMin/Apc+
Glp2rtm1Ddr/Glp2r+

(involves: C57BL/6J)
abnormal tumor morphology J:141821
increased intestinal adenoma incidence J:141821
ApcMin/Apc+
Glp2rtm1Ddr/Glp2rtm1Ddr

(involves: C57BL/6J)
abnormal tumor morphology J:141821
increased intestinal adenoma incidence J:141821
ApcMin/Apc+
Gpa33tm1(GNAS)Wtsi/Gpa33+
Hprttm1(CMV-cre)Brd/?

(involves: 129S7/SvEvBrd * C57BL/6J)
increased intestinal adenoma incidence J:168378
ApcMin/Apc+
Gt(ROSA)26Sor/Gt(ROSA)26Sor+

(B6.Cg-Gt(ROSA)26Sor ApcMin)
altered tumor susceptibility J:66060
decreased alimentary system tumor incidence J:66060
decreased incidence of tumors by chemical induction J:66060
decreased mammary gland tumor incidence J:66060
ApcMin/Apc+
Gt(ROSA)26Sortm2(Rnf187)Jhai/Gt(ROSA)26Sor+
Tg(Vil1-cre)20Syr/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
increased gastrointestinal tumor incidence J:173145
increased tumor growth/size J:173145
ApcMin/Apc+
Hdac2Gt(W035F03)Joe/Hdac2Gt(W035F03)Joe

(involves: 129S2/SvPas * C57BL/6J)
decreased tumor incidence J:152134
increased small intestine adenocarcinoma incidence J:152134
ApcMin/Apc+
Hltftm1.1Hdin/Hltftm1.1Hdin

(involves: 129 * C57BL/6 * FVB/N)
increased metastatic potential J:252991
neoplasm J:252991
ApcMin/Apc+
Hptm1Skl/Hptm1Skl

(involves: 129P2/OlaHsd * C57BL/6J)
increased gastrointestinal tumor incidence J:75249
ApcMin/Apc+
Hpgdstm1Urad/Hpgds+

(involves: 129 * C57BL/6J)
increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Hpgdstm1Urad/Hpgdstm1Urad

(involves: 129 * C57BL/6J)
increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Hsd11b2tm1.1Mzz/Hsd11b2tm1.1Mzz
Tg(Vil1-cre)997Gum/0

(involves: 129 * C57BL/6 * C57BL/6J)
decreased tumor growth/size J:205456
increased intestinal adenoma incidence J:205456
ApcMin/Apc+
Igf2bp1tm1Vssp/Igf2bp1tm1Vssp
Tg(Vil1-cre)997Gum/0

(involves: C57BL/6J * SJL)
abnormal tumor incidence J:202774
ApcMin/Apc+
Il6tm1Kopf/Il6tm1Kopf

(involves: 129S2/SvPas * C57BL/6)
abnormal tumor incidence J:130429
ApcMin/Apc+
Il22tm1Flv/Il22tm1Flv

(involves: 129/Sv * C57BL/6 * C57BL/6J)
decreased alimentary system tumor incidence J:189217
ApcMin/Apc+
Il22ra2tm2Vlcg/Il22ra2tm2Vlcg

(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)
increased intestinal adenoma incidence J:189217
increased tumor growth/size J:189217
ApcMin/Apc+
Mapkapk2tm1.1Gkl/Mapkapk2tm1.1Gkl
Tg(Tie1-cre)9Ref/0

(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6J)
decreased tumor growth/size J:262876
ApcMin/Apc+
Mapkapk2tm1.1Gkl/Mapkapk2tm1.1Gkl
Twist2tm1.1(cre)Dor/Twist2+

(involves: 129X1/SvJ * BALB/cJ * C57BL/6J)
decreased tumor growth/size J:262876
decreased tumor incidence J:262876
ApcMin/Apc+
Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl

(involves: BALB/cJ * C57BL/6J)
abnormal tumor vascularization J:262876
decreased tumor growth/size J:262876
decreased tumor incidence J:262876
increased intestinal adenoma incidence J:262876
ApcMin/Apc+
Mbd2tm1Bh/Mbd2+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
decreased tumor incidence J:83087
ApcMin/Apc+
Mbd2tm1Bh/Mbd2tm1Bh

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
decreased tumor growth/size J:83087
decreased tumor incidence J:83087
ApcMin/Apc+
Mbd4tm1Bird/Mbd4tm1Bird

(involves: 129P2/OlaHsd * C57BL/6J)
increased intestinal adenoma incidence J:77896
ApcMin/Apc+
Mir10atm1.1Ahl/Mir10atm1.1Ahl

(B6.Cg-Mir10atm1.1Ahl Apcmin)
increased gastrointestinal tumor incidence J:205135
increased intestinal adenoma incidence J:205135
ApcMin/Apc+
Mmom1C57BL/6J/Mmom1FVB/NTac

(involves: C57BL/6J * FVB/NTac)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmom1C57BL/6J/Mmom1FVB/NTac
Mmom3C57BL/6J/Mmom3FVB/NTac

(involves: C57BL/6J * FVB/NTac)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmom2129X1/SvJ/Mmom2C57BL/6J

(involves: 129X1/SvJ * C57BL/6J)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmom2C57BL/6J/Mmom2FVB/NTac

(involves: C57BL/6J * FVB/NTac)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmom2C57BL/6J/Mmom2FVB/NTac
Mmom3C57BL/6J/Mmom3FVB/NTac

(involves: C57BL/6J * FVB/NTac)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmom2C57BL/6J/Mmom2FVB/NTac
Mmom4C57BL/6J/Mmom4FVB/NTac

(involves: C57BL/6J * FVB/NTac)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmom4C57BL/6J/Mmom4FVB/NTac

(involves: C57BL/6J * FVB/NTac)
decreased mammary gland tumor incidence J:128481
ApcMin/Apc+
Mmp7tm1Lmm/Mmp7tm1Lmm

(involves: C57BL/6 * C57BL/6J)
abnormal tumor morphology J:38609
increased tumor incidence J:38609
ApcMin/Apc+
Mom5129P2/OlaHsd/?

(involves: 129P2/OlaHsd * C57BL/6J)
decreased incidence of induced tumors J:152194
ApcMin/Apc+
Mom5C57BL/6J/Mom5C57BL/6J

(involves: C57BL/6J)
increased intestinal adenoma incidence J:152194
ApcMin/Apc+
Msh2tm1Htr/Msh2tm1Htr

(involves: 129P2/OlaHsd * BALB/c * C57BL/6J)
increased gastrointestinal tumor incidence J:45433
ApcMin/Apc+
Msh2tm1Mak/Msh2tm1Mak

(involves: 129P2/OlaHsd * C57BL/6J)
increased intestinal adenoma incidence J:75393
ApcMin/Apc+
MthfsGt(RRK291)Byg/Mthfs+

(B6.Cg-MthfsGt(RRK291)Byg ApcMin)
neoplasm J:185874
ApcMin/Apc+
Nos2tm1Lau/Nos2+

(B6.Cg-Nos2tm1Lau ApcMin)
decreased tumor growth/size J:73152
decreased tumor incidence J:73152
ApcMin/Apc+
Nos2tm1Lau/Nos2tm1Lau

(B6.Cg-Nos2tm1Lau ApcMin)
decreased tumor growth/size J:73152
decreased tumor incidence J:73152
ApcMin/Apc+
Phgdhtm1.1Shfu/Phgdh+

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
neoplasm J:183477
ApcMin/Apc+
Pla2g2aMom1-r/?
Prkdcdxnph/Prkdcdxnph

(involves: BALB/cByJ * C57BL/6)
increased incidence of tumors by ionizing radiation induction J:83497
ApcMin/Apc+
Pla2g2aMom1-r/Pla2g2a+

(either: (AKR/J x C57BL/6J-ApcMin)F1 or (MA/MyJ x C57BL/6J-ApcMin)F1 or (CAST/EiJ x C57BL/6J-ApcMin)F1)
decreased alimentary system tumor incidence J:15703
decreased intestinal adenoma incidence J:15703
ApcMin/Apc+
Pms2tm1Lisk/Pms2tm1Lisk

(involves: 129S2/SvPas * C57BL/6J)
increased intestinal adenoma incidence J:46419
ApcMin/Apc+
Ppardtm1Jps/Ppardtm1Jps

(involves: 129/Sv * AKR/J * C57BL/6 * C57BL/6J)
increased intestinal adenocarcinoma incidence J:90337
ApcMin/Apc+
Ptentm1Hwu/Ptentm1Hwu
Tg(Vil1-cre)997Gum/0

(involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL)
increased intestinal adenoma incidence J:150553
ApcMin/Apc+
Ptgdstm1Ohy/Ptgdstm1Ohy

(involves: 129P2/OlaHsd * C57BL/6J)
increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Ptgs1tm1Unc/Ptgs1+

(involves: 129P2/OlaHsd * C57BL/6J)
decreased tumor incidence J:64401
ApcMin/Apc+
Ptgs1tm1Unc/Ptgs1tm1Unc

(involves: 129P2/OlaHsd * C57BL/6J)
decreased tumor incidence J:64401
ApcMin/Apc+
Ptgs2tm1Unc/Ptgs2tm1Unc

(involves: 129P2/OlaHsd * C57BL/6J)
decreased tumor incidence J:64401
ApcMin/Apc+
Ptprhtm1.1Mato/Ptprhtm1.1Mato

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
decreased incidence of induced tumors J:146871
ApcMin/Apc+
Rab25tm1Jrgo/Rab25+

(B6.Cg-Rab25tm1Jrgo ApcMin)
increased intestinal adenoma incidence J:158733
ApcMin/Apc+
Rab25tm1Jrgo/Rab25tm1Jrgo

(B6.Cg-Rab25tm1Jrgo ApcMin)
increased colon adenoma incidence J:158733
increased intestinal adenoma incidence J:158733
ApcMin/Apc+
Recql4tm1Glu/Recql4tm1Glu

(involves: 129S7/SvEvBrd * C57BL/6J)
increased adenoma incidence J:97101
increased colon adenoma incidence J:97101
increased tumor growth/size J:97101
ApcMin/Apc+
Shmt1Gt(AD0236)Wtsi/Shmt1Gt(AD0236)Wtsi

(B6.Cg-Shmt1Gt(AD0236)Wtsi ApcMin)
neoplasm J:183477
ApcMin/Apc+
Slc5a8tm1.1Boet/Slc5a8tm1.1Boet

(involves: C57BL/6 * C57BL/6J)
increased colon adenoma incidence J:139883
ApcMin/Apc+
Spata13tm1Taki/Spata13+

(B6J.Cg-Spata13tm1Taki ApcMin)
decreased intestinal adenoma incidence J:157023
decreased tumor growth/size J:157023
ApcMin/Apc+
Spata13tm1Taki/Spata13tm1Taki

(B6J.Cg-Spata13tm1Taki ApcMin)
decreased intestinal adenoma incidence J:157023
decreased tumor growth/size J:157023
ApcMin/Apc+
Spata18tm1.2Hifa/Spata18+

(involves: C57BL/6J)
altered tumor susceptibility J:254117
increased classified tumor incidence J:254117
increased colon adenocarcinoma incidence J:254117
increased colon adenoma incidence J:254117
increased intestinal adenocarcinoma incidence J:254117
increased intestinal adenoma incidence J:254117
increased small intestine adenocarcinoma incidence J:254117
ApcMin/Apc+
Spata18tm1.2Hifa/Spata18tm1.2Hifa

(involves: C57BL/6J)
altered tumor susceptibility J:254117
increased classified tumor incidence J:254117
increased colon adenocarcinoma incidence J:254117
increased colon adenoma incidence J:254117
increased intestinal adenocarcinoma incidence J:254117
increased intestinal adenoma incidence J:254117
increased small intestine adenocarcinoma incidence J:254117
ApcMin/Apc+
Tcf7tm1Cle/Tcf7tm1Cle

(involves: 129P2/OlaHsd * C57BL/6J)
increased intestinal adenoma incidence J:57721
increased mammary adenoacanthoma incidence J:57721
increased salivary gland tumor incidence J:57721
ApcMin/Apc+
Tcf7l2tm1(EGFP/cre)Mrc/Tcf7l2tm2.1Mrc

(involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6J * C57BL/6NCrl)
neoplasm J:170088
ApcMin/Apc+
Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased intestinal adenoma incidence J:170088
ApcMin/Apc+
Tcf7l2tm2.2Mrc/Tcf7l2+

(involves: C57BL/6J)
increased intestinal adenoma incidence J:170088
ApcMin/Apc+
Tg(CAG-PGDS)S-55Hjl/0

(involves: C57BL/6J * FVB/N)
increased intestinal adenoma incidence J:118232
ApcMin/Apc+
Tg(Vil1-PPARGC1A)#Amos/0

(involves: C57BL/6J * FVB/N)
decreased alimentary system tumor incidence J:171361
decreased tumor growth/size J:171361
ApcMin/Apc+
Tgfbr1tm1Bopa/Tgfbr1+

(involves: 129S1/SvImJ * C57BL/6J)
increased gastrointestinal tumor incidence J:143706
increased intestinal adenocarcinoma incidence J:143706
ApcMin/Apc+
Tgfbr1tm1Bopa/Tgfbr1+

(B6.Cg-Tgfbr1tm1Bopa ApcMin)
increased gastrointestinal tumor incidence J:143706
increased intestinal adenocarcinoma incidence J:143706
ApcMin/Apc+
Thbs1tm1Hyn/Thbs1tm1Hyn

(involves: C57BL/6J)
increased carcinoma incidence J:79641
increased intestinal adenoma incidence J:79641
increased tumor incidence J:79641
ApcMin/Apc+
Tniktm1Teya/Tniktm1Teya

(involves: C57BL/6J)
decreased alimentary system tumor incidence J:241611
ApcMin/Apc+
Trp53tm1Mlh/Trp53tm1Mlh

(involves: 129P2/OlaHsd * C57BL/6 * SWR)
increased pancreatic acinar cell carcinoma incidence J:29664
ApcMin/Apc+
Zbtb33tm1.1Bird/Y

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
decreased tumor growth/size J:104155
increased intestinal adenoma incidence J:104155
ApcMin/ApcMin
Asphtm1Jed/Asphtm1Jed

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6J * C57BL/6NTac)
increased gastrointestinal tumor incidence J:75888
ApcMin/ApcMin
Ppardtm1.1Rev/Ppardtm1.1Rev

(involves: C57BL/6J)
increased intestinal adenoma incidence J:73557
ApcMin/ApcMin
Rr27tm1Rohl/Rr27+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased colon adenoma incidence J:97083
increased intestinal adenoma incidence J:97083
ApcMin/ApcMin
Sat1tm1Alh/Y

(involves: 129X1/SvJ * C57BL/6J)
decreased tumor incidence J:99381
ApcMin/Apctm1Tno
Ctnnb1tm4.1Wbm/Ctnnb1+

(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased hepatocellular carcinoma incidence J:156864
Apctm1.1Alew/Apc+
(B6.129-Apctm1.1Alew)
abnormal tumor morphology J:180275
increased adenoma incidence J:180057
increased intestinal adenoma incidence J:180057, J:180275
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd)
increased gastrointestinal tumor incidence J:149225
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased desmoid tumor incidence J:159883
increased gastrointestinal tumor incidence J:159883
increased intestinal adenoma incidence J:159883
increased large intestine adenocarcinoma incidence J:159883
increased small intestine adenocarcinoma incidence J:159883
Apctm1.1Tno/Apc+
(involves: 129S4/SvJae * C57BL/6)
increased intestinal adenoma incidence J:127452
Apctm1.1Tno/Apc+
Ctnna1del/Ctnna1+

(involves: 129S4/SvJae * C57BL/6)
neoplasm J:127452
Apctm1.1Tyj/Apc+
(involves: 129S4/SvJaeSor * C57BL/6)
increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
increased tumor growth/size J:160399
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
increased colon adenoma incidence J:94108
increased intestinal adenocarcinoma incidence J:94108
increased intestinal adenoma incidence J:94108
increased mammary adenocarcinoma incidence J:94108
Apctm1Cip/Apc+
H19tm1Lda/H19+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
increased adenoma incidence J:138826
increased intestinal adenocarcinoma incidence J:138826
Apctm1Cip/Apc+
H19tm1Lda/H19+

(involves: 129P2/OlaHsd * 129S2/SvPas)
increased adenoma incidence J:138826
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
increased gastrointestinal tumor incidence J:61978
increased mammary adenocarcinoma incidence J:61978
increased mammary gland tumor incidence J:61978
increased stomach tumor incidence J:61978
Apctm1Kk/Apctm1Kk
Tg(Lck-cre)1Cwi/?

(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
increased intestinal adenoma incidence J:104334
Apctm1Mmt/Apc+
(involves: 129S2/SvPas * C57BL/6J)
increased intestinal adenoma incidence J:79668, J:25200
Apctm1Mmt/Apc+
Mmp7tm1Lmm/Mmp7tm1Lmm
Smad4tm1Mmt/Smad4+

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
decreased tumor growth/size J:142797
decreased tumor incidence J:142797
Apctm1Mmt/Apc+
Smad2tm1Kato/Smad2+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
increased intestinal adenoma incidence J:79668
Apctm1Mmt/Apc+
Smad2tm2Kato/Smad2+

(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
increased intestinal adenoma incidence J:79668
Apctm1Mmt/Apc+
Smad4tm1Mmt/Smad4+

(involves: 129S2/SvPas * C57BL/6)
increased intestinal adenocarcinoma incidence J:46242
increased pancreatic ductal adenocarcinoma incidence J:46242
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
increased hepatocellular carcinoma incidence J:20443
increased intestinal adenocarcinoma incidence J:20443
increased intestinal adenoma incidence J:20443
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6J)
increased intestinal adenocarcinoma incidence J:65142
increased stomach tumor incidence J:65142
Apctm1Rak/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
increased desmoid tumor incidence J:151494
increased gastrointestinal tumor incidence J:151494
increased stomach tumor incidence J:151494
Apctm1Rak/Apc+
Cdh1tm1Cbm/Cdh1+

(involves: 129P2/OlaHsd * C57BL/6J)
increased intestinal adenocarcinoma incidence J:65142
increased stomach tumor incidence J:65142
Apctm1Rak/Apc+
Dcctm1.1Mehl/Dcctm1.1Mehl

(involves: 129P2/OlaHsd * C57BL/6)
increased gastrointestinal tumor incidence J:181517
increased intestinal adenocarcinoma incidence J:181517
increased metastatic potential J:181517
Apctm1Rak/Apc+
Hmmrtm1Baa/Hmmrtm1Baa

(involves: 129P2/OlaHsd * C57BL/6)
decreased tumor incidence J:86065
Apctm1Rak/Apc+
Mbd4tm1Wed/Mbd4tm1Wed

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL)
increased gastrointestinal tumor incidence J:80319
Apctm1Rak/Apc+
Mlh1tm1Rak/Mlh1+

(involves: 129P2/OlaHsd * C57BL/6)
increased gastrointestinal tumor incidence J:53451
increased tumor incidence J:53451
Apctm1Rak/Apc+
Mlh1tm1Rak/Mlh1tm1Rak

(involves: 129P2/OlaHsd * C57BL/6)
increased adenocarcinoma incidence J:53451
increased adenoma incidence J:53451
increased carcinoma incidence J:53451
increased gastrointestinal tumor incidence J:53451
increased lymphoma incidence J:53451
increased skin tumor incidence J:53451
increased tumor incidence J:53451
Apctm1Rak/Apc+
Msh2tm1Rak/Msh2tm1Rak

(involves: 129P2/OlaHsd)
increased tumor incidence J:64667
Apctm1Rak/Apc+
Smad4E6sad/Smad4+

(B6.129P2-Apctm1Rak Smad4E6sad/+ +)
increased intestinal adenoma incidence J:107273
Apctm1Rak/Apc+
Smad4E6sad/Smad4+

(B6.129P2-Apctm1Rak +/+ Smad4E6sad)
increased intestinal adenocarcinoma incidence J:107273
increased intestinal adenoma incidence J:107273
Apctm1Rfo/Apctm1Rfo
(involves: 129P2/OlaHsd * C57BL/6J)
neoplasm J:55416
Apctm1Rsmi/Apc+
Ctnnb1tm1Wvv/Ctnnb1+
Tg(Fabp1-cre)1Jig/?

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
increased gastrointestinal tumor incidence J:185942
Apctm1Rsmi/Apc+
Tg(Fabp1-cre)1Jig/0

(involves: 129P2/OlaHsd * FVB/N)
increased gastrointestinal tumor incidence J:159883
increased intestinal adenocarcinoma incidence J:159883
increased intestinal adenoma incidence J:159883
increased large intestine adenocarcinoma incidence J:159883
increased small intestine adenocarcinoma incidence J:159883
Apctm1Rsmi/Apctm1Rsmi
(involves: 129P2/OlaHsd)
neoplasm J:149225
Apctm1Rsmi/Apctm1Rsmi
Pgrtm2(cre)Lyd/Pgr+

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
increased granulosa cell tumor incidence J:210095
increased ovary tumor incidence J:210095
increased reproductive system tumor incidence J:210095
Apctm1Tno/Apc+
(involves: 129 * 129S4/SvJae * C57BL/6)
increased hepatocellular carcinoma incidence J:156864
Apctm1Tno/Apc+
Il17ratm1Koll/Il17ratm1Koll
Tg(CDX2-cre)101Erf/0

(involves: 129 * 129S4/SvJae * C57BL/6J * SJL/J)
decreased tumor growth/size J:189226
Apctm1Tno/Apc+
Il23atm1Ngh/Il23atm1Ngh
Tg(CDX2-cre)101Erf/0

(involves: 129 * 129S4/SvJae * C57BL/6J * SJL/J)
decreased tumor growth/size J:189226
Apctm1Tno/Apc+
Il23rtm1.2Trin/Il23rtm1.2Trin
Tg(CDX2-cre)101Erf/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * SJL/J)
decreased tumor growth/size J:189226
Apctm1Tno/Apc+
Ptentm2Mak/Ptentm2Mak
Tg(Cyp1a1-cre/ERT)1Dwi/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
increased intestinal adenocarcinoma incidence J:143082
Apctm1Tno/Apc+
Tg(CDX2-cre)101Erf/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
increased gastrointestinal tumor incidence J:126018
increased mammary adenocarcinoma incidence J:126018
increased tumor incidence J:126018
Apctm1Tno/Apc+
Tg(CDX2-cre*)189Erf/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
neoplasm J:148161
Apctm1Tno/Apc+
Tg(CDX2-cre/ERT)#Erf/0

(involves: 129S4/SvJae)
increased gastrointestinal tumor incidence J:189226
Apctm1Tno/Apc+
Tg(Vil1-cre)997Gum/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
increased gastrointestinal tumor incidence J:126018
increased small intestine adenocarcinoma incidence J:126018
Apctm1Tno/Apctm1Tno
(involves: 129S4/SvJae * C57BL/6)
increased colon adenoma incidence J:43301
Apctm1Tno/Apctm1Tno
(involves: 129 * 129S4/SvJae * C57BL/6)
increased hepatocellular carcinoma incidence J:156864
increased incidence of tumors by chemical induction J:156864
Apctm1Tno/Apctm1Tno
Ctnnb1tm4.1Wbm/Ctnnb1+

(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
decreased tumor incidence J:156864
Apctm1Tno/Apctm1Tno
Elp3tm1.1Tac/Elp3tm1.1Tac
Lgr5tm1(cre/ERT2)Cle/Lgr5+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
decreased tumor growth/size J:227334
Apctm1Tno/Apctm1Tno
Lgr5tm1(cre/ERT2)Cle/Lgr5+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased intestinal adenoma incidence J:227334
Apctm1Tno/Apctm1Tno
Ptentm2Mak/Ptentm2Mak

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased ovarian carcinoma incidence J:120955
Apctm1Tno/Apctm1Tno
Tg(Cdh16-cre)91Igr/0

(involves: 129S4/SvJae * ICR)
increased renal cystadenoma incidence J:95502
Apctm1Tno/Apctm1Tno
Tg(CDX2-cre*)189Erf/0

(involves: 129S4/SvJae * C57BL/6 * SJL)
increased colon adenoma incidence J:148161
Apctm1Tno/Apctm1Tno
Tg(Pbsn-cre)4Prb/0

(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
increased prostate gland adenocarcinoma incidence J:120308
increased prostate intraepithelial neoplasia incidence J:120308
increased tumor incidence J:120308
Apctm1Tyj/Apc+
Tg(Vil1-cre)20Syr/0

(involves: C57BL/6 * DBA/2)
increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm2.1Alew/Apc+
(B6.129-Apctm2.1Alew)
altered tumor pathology J:180057
increased adenoma incidence J:180057
increased intestinal adenoma incidence J:180057
Apctm2.1Cip/Apc+
Atg7tm1Tchi/Atg7tm1Tchi
Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2)
decreased intestinal adenoma incidence J:227287
Apctm2.1Cip/Apc+
Krastm4Tyj/Kras+
Tg(Fabp1-cre)1Jig/0

(involves: 129P2/OlaHsd * 129S4/SvJae * FVB)
increased intestinal adenocarcinoma incidence J:132357
Apctm2.1Cip/Apc+
Lgr5tm1(cre/ERT2)Cle/Lgr5+

(involves: 129P2/OlaHsd * C57BL/6)
neoplasm J:186084
Apctm2.1Cip/Apc+
Lrig1tm1.1(cre/ERT2)Rjc/Lrig1+

(involves: 129 * 129P2/OlaHsd * C57BL/6)
increased intestinal adenoma incidence J:186084
Apctm2.1Cip/Apc+
Tg(Fabp1-cre)1Jig/0

(involves: 129P2/OlaHsd * FVB/N)
increased intestinal adenocarcinoma incidence J:132357
Apctm2.1Cip/Apc+
Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased colon adenoma incidence J:160399
increased intestinal adenoma incidence J:160399
Apctm2.1Cip/Apc+
Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased colon adenoma incidence J:227287
increased intestinal adenoma incidence J:227287
Apctm2.1Cip/Apctm2.1Cip
(involves: 129P2/OlaHsd * C57BL/6N)
increased hepatocellular carcinoma incidence J:94721
Apctm2.1Rak/Apc+
(involves: 129/Sv * C57BL/6J * SJL)
increased gastrointestinal tumor incidence J:114152
increased intestinal adenoma incidence J:114152
Apctm2Mmt/Apc+
(involves: 129X1/SvJ)
increased intestinal adenoma incidence J:81402
Apctm2Rak/Apc+
Tg(Car1-cre)5Flt/0

(involves: 129/Sv * C57BL/6J * SJL)
increased incidence of tumors by chemical induction J:164247
increased intestinal adenoma incidence J:164247
neoplasm J:164247
Apctm2Rak/Apc+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
increased cystadenoma incidence J:234310
increased metastatic potential J:234310
increased pancreas tumor incidence J:234310
Apctm2Rak/Apctm2Rak
(involves: 129/Sv * C57BL/6J * SJL)
increased carcinoma incidence J:156532
increased colon adenoma incidence J:156532
increased organ/body region tumor incidence J:156532
Apctm2Rak/Apctm2Rak
Krastm4Tyj/Kras+

(involves: 129 * 129S4/SvJae * C57BL/6J * SJL)
increased adenocarcinoma incidence J:156532
increased carcinoma incidence J:156532
increased colon adenoma incidence J:156532
increased organ/body region tumor incidence J:156532
Apctm2Rak/Apctm2Rak
Tg(Car1-cre)5Flt/0

(involves: 129/Sv * C57BL/6J * SJL)
increased intestinal adenoma incidence J:164247
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo)
increased liver tumor incidence J:151494
increased mammary adenocarcinoma incidence J:151494
increased mammary gland tumor incidence J:151494
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
increased desmoid tumor incidence J:151494
increased liver tumor incidence J:151494
increased mammary adenocarcinoma incidence J:204440, J:151494
increased mammary gland tumor incidence J:151494
increased metastatic potential J:204440
increased tumor incidence J:151494
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo)
increased gastrointestinal tumor incidence J:151494
increased liver tumor incidence J:151494
increased mammary adenocarcinoma incidence J:151494
Apctm2Rfo/Apc+
Smad4E6sad/Smad4+

(involves: 129P2/OlaHsd * C57BL/6J)
increased gastrointestinal tumor incidence J:151494
increased mammary adenocarcinoma incidence J:151494
Apctm2Tno/Apc+
(Not Specified)
increased intestinal adenoma incidence J:47857
Apctm3Mmt/Apc+
(B6.129X1-Apctm3Mmt)
increased intestinal adenoma incidence J:101604
Apctm4Mmt/Apc+
(B6.129X1-Apctm4Mmt)
increased intestinal adenoma incidence J:101604
Apex1tm1Ecf/Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
increased carcinoma incidence J:70397
increased lymphoma incidence J:70397
increased sarcoma incidence J:70397
increased tumor incidence J:70397
Apex1tm1Ecf/Apex1+
Xpctm1Ecf/Xpctm1Ecf

(involves: 129)
increased tumor incidence J:70397
Apmt1FVB/NJ/Apmt1FVB/NJ
(involves: FVB/NJ * I/LnJ)
increased mammary gland tumor incidence J:64663
Apmt1FVB/NJ/Apmt1FVB/NJ
Apmt2I/LnJ/Apmt2FVB/NJ

(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
increased mammary gland tumor incidence J:64663
Apmt1FVB/NJ/Apmt1I/LnJ
(involves: FVB/NJ * I/LnJ)
increased mammary gland tumor incidence J:64663
Apmt2I/LnJ/?
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
increased mammary gland tumor incidence J:64663
Apobec3Rfv3-r/Apobec3+
((B10.A x A)F1)
abnormal tumor morphology J:6147
ArTfm/Y
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
increased testis tumor incidence J:140803
ArTfm/Y
Tg(TSPY)9Jshm/0

(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
increased testis tumor incidence J:140803
Artm1(AR)Dmr/Y
Tg(TRAMP)8247Ng/0

(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:108849
Artm1.1Chc/Y
(involves: 129S/SvEv * C57BL/6 * FVB/N)
abnormal tumor morphology J:120844
decreased incidence of tumors by chemical induction J:120844
preneoplasia J:120844
Artm1.1Chc/Artm1.1Chc
(involves: 129S/SvEv * C57BL/6 * FVB/N)
decreased incidence of tumors by chemical induction J:120844
preneoplasia J:120844
Artm1Verh/Y
Ptentm1Hwu/Ptentm1Hwu
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:172730
Artm2(AR)Dmr/Y
Tg(TRAMP)8247Ng/0

(involves: 129S1/Sv * C57BL/6)
increased prostate gland tumor incidence J:108849
Artm3(AR)Dmr/Y
Tg(TRAMP)8247Ng/0

(involves: 129S1/Sv * C57BL/6)
decreased tumor incidence J:108849
Artm3.1(AR)Ska/Y
Tg(KLKB1-cre/ERT2)1Pcn/0
Tg(TRAMP)8247Ng/0

(involves: C57BL/6 * C57BL/6J * CBA)
abnormal tumor morphology J:170092
decreased tumor latency J:170092
increased prostate gland tumor incidence J:170092
increased tumor growth/size J:170092
Arhgef4tm1Taki/Arhgef4tm1Taki
(involves: C57BL/6 * C57BL/6J * CBA)
abnormal tumor morphology J:159959
abnormal tumor vascularization J:159959
decreased tumor growth/size J:159959
Arhgef15tm1(KOMP)Vlcg/Arhgef15tm1(KOMP)Vlcg
(involves: C57BL/6NTac)
neoplasm J:188649
Arid1atm1.1Mag/Arid1a+
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * CD-1)
neoplasm J:219794
Arid1atm1.1Mag/Arid1atm1.1Mag
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+

(involves: 129S6/SvEvTac * CD-1)
increased metastatic potential J:219794
increased ovarian carcinoma incidence J:219794
increased ovary tumor incidence J:219794
Arid4atm1Alb/Arid4atm1Alb
(involves: 129S7/SvEvBrd)
increased leukemia incidence J:141004
increased sarcoma incidence J:141004
Arid4atm1Alb/Arid4atm1Alb
Arid4btm1Alb/Arid4b+

(involves: 129S7/SvEvBrd)
increased leukemia incidence J:141004
increased sarcoma incidence J:141004
Arl6ip5tm1.2Jwzh/Arl6ip5tm1.2Jwzh
(B6.129X1-Arl6ip5tm1.2Jwzh)
decreased incidence of tumors by chemical induction J:187133
decreased tumor growth/size J:187133
neoplasm J:187133
Arnttm1Bra/Arnttm1Bra
Hprttm1(Pck1-cre)Vhh/Y
Vhltm1Jae/Vhltm1Jae

(involves: 129 * BALB/c * C57BL/6)
neoplasm J:97652
Asap1Gt(RRS873)Byg/Asap1Gt(RRS873)Byg
(FVB.129P2(B6)-Asap1Gt(RRS873)Byg)
neoplasm J:277387
Asxl1tm1.1Mjxu/Asxl1+
(involves: 129 * C57BL/6)
increased leukemia incidence J:208085
increased malignant tumor incidence J:208085
increased sarcoma incidence J:208085
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd)
increased gland tumor incidence J:176672
increased granulosa cell tumor incidence J:176672
increased Harderian gland adenocarcinoma incidence J:176672
increased hemangiosarcoma incidence J:176672
increased liver adenocarcinoma incidence J:176672
increased lung adenocarcinoma incidence J:176672
increased lung carcinoma incidence J:176672
increased lymphoma incidence J:176672
increased sarcoma incidence J:176672
increased spindle cell carcinoma incidence J:176672
increased T cell derived lymphoma incidence J:176672
increased tumor incidence J:176672
Atf2Tg(Gzma-Klra1)7Wum/Atf2+
(involves: C57BL/6)
increased metastatic potential J:61178
Atf2tm3Nicj/Atf2tm3Nicj
Tg(KRT14-cre)1Efu/?

(involves: C57BL/6 * FVB/N)
increased skin papilloma incidence J:131564
Atf3tm1.1Hai/Atf3tm1.1Hai
Lyz2tm1(cre)Ifo/Lyz2+

(involves: 129P2/OlaHsd * FVB/N)
decreased metastatic potential J:201626
Atf3tm1Dron/Atf3tm1Dron
(involves: 129X1/SvJ * C57BL/6)
decreased metastatic potential J:201626
neoplasm J:201626
Atf3tm1Dron/Atf3tm1Dron
Tg(MMTV-PyVT)634Mul/0

(involves: 129X1/SvJ * C57BL/6 * FVB/N)
decreased metastatic potential J:201626
decreased tumor growth/size J:201626
Atg4ctm1Otin/Atg4ctm1Otin
(involves: 129P2/OlaHsd * C57BL/6)
increased incidence of tumors by chemical induction J:123386
Atmtm1.1Mmpl/Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
increased T cell derived lymphoma incidence J:226414
Atmtm1Awb/Atm+
Rad50tm2Jpt/Rad50tm2Jpt

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))
increased T cell derived lymphoma incidence J:34193
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6)
increased T cell derived lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac)
increased T cell derived lymphoma incidence J:90941
Atmtm1Awb/Atmtm1Awb
(CByJ.129S6-Atmtm1Awb)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(B6.129S6-Atmtm1Awb)
abnormal tumor incidence J:208539
Atmtm1Awb/Atmtm1Awb
(A.129S6-Atmtm1Awb)
altered tumor susceptibility J:208539
increased hepatocellular carcinoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
increased T cell derived lymphoma incidence J:208539
Atmtm1Awb/Atmtm1Awb
(either: (A.129S6-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x A.129S6-Atmtm1Awb)F1)
abnormal tumor incidence J:208539
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J)
increased T cell derived lymphoma incidence J:226414
Atmtm1Awb/Atmtm1Awb
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0

(involves: 129 * C57BL * FVB/N * SJL)
increased tumor incidence J:120284
Atmtm1Awb/Atmtm1Awb
Rad50tm2Jpt/Rad50tm2Jpt

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
increased lymphoma incidence J:103922
Atmtm1Awb/Atmtm1Awb
Rad50tm4.1Jpt/Rad50+

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
increased tumor latency J:209141
Atmtm1Awb/Atmtm1Awb
Rad52tm1Aps/Rad52tm1Aps

(involves: 129P2/OlaHsd * 129S6/SvEvTac)
decreased lymphoma incidence J:90941
increased T cell derived lymphoma incidence J:90941
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:35914
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6)
increased T cell derived lymphoma incidence J:61201
Atmtm1Led/Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss)
increased T cell derived lymphoma incidence J:69726
increased thymoma incidence J:36561
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J)
increased adenoma incidence J:78527
increased leukemia incidence J:78527
increased lymphoma incidence J:78527
increased ovary tumor incidence J:78527
increased sarcoma incidence J:78527
increased tumor incidence J:78527
Atmtm1Mfl/Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J)
increased T cell derived lymphoma incidence J:69726
increased tumor incidence J:69726
Atmtm1Pmc/Atmtm1Pmc
(involves: 129X1/SvJ * C57BL/6)
increased lymphoma incidence J:47752
Atmintm1.1Jhh/Atmintm1.1Jhh
Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0

(B6.Cg-Bcl2l11tm1.1Ast Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
increased lymphoma incidence J:230105
Atmintm1.1Jhh/Atmintm1.1Jhh
Cd79atm1(cre)Reth/Cd79a+
Tg(IghMyc)22Bri/0

(B6.Cg-Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
decreased lymphoma incidence J:230105
increased tumor latency J:230105
Atmintm1.1Jhh/Atmintm1.1Jhh
Ighmtm1(Bcl6)Rdf/Ighm+
Tg(Fcer2a-cre)5Mbu/0

(B6.Cg-Atmintm1.1Jhh Ighmtm1(Bcl6)Rdf Tg(Fcer2a-cre)5Mbu)
altered tumor susceptibility J:230105
Atmintm1.1Jhh/Atmintm1.1Jhh
Tg(Fcer2a-cre)5Mbu/0

(B6.Cg-Atmintm1.1Jhh Tg(Fcer2a-cre)5Mbu)
neoplasm J:230105
Atp2a2tm1Ges/Atp2a2+
(involves: 129X1/SvJ * Black Swiss)
increased esophageal papilloma incidence J:69754
increased skin papilloma incidence J:69754
increased squamous cell carcinoma incidence J:69754
increased tongue papilloma incidence J:69754
increased tumor incidence J:69754
Atp2c1tm1Ges/Atp2c1+
(involves: 129X1/SvJ * Black Swiss)
increased esophageal papilloma incidence J:124662
increased skin papilloma incidence J:124662
increased squamous cell carcinoma incidence J:124662
Atp4atm1.1Ocalv/Atp4atm1.1Ocalv
(involves: 129S6/SvEv * C57BL/6J * C57BL/6NCrl)
neoplasm J:235360
Atp6v0a2tm1Kdb/Atp6v0a2tm1Kdb
Commd10Tg(Vav1-icre)A2Kio/Commd10+

(involves: C57BL/6 * C57BL/10 * CBA/Ca)
decreased tumor latency J:274048
increased incidence of induced tumors J:274048
increased metastatic potential J:274048
Atp11cambr/Y
(C57BL/6-Atp11cambr)
increased hepatocellular carcinoma incidence J:171924
Atrtm1Akl/Atr+
(involves: 129P2/OlaHsd * C57BL/6)
neoplasm J:61732
Atrtm1Bal/Atr+
(involves: 129 * C57BL/6)
increased tumor incidence J:60768
AurkaGt(XQ0149)Wtsi/Aurka+
(involves: 129P2/OlaHsd * C57BL/6)
increased hepatoma incidence J:143099
increased lung carcinoma incidence J:143099
increased lymphoma incidence J:143099
increased squamous cell carcinoma incidence J:143099
increased tumor incidence J:143099
Aurkbtm1.2Mama/Aurkb+
(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL)
increased adenocarcinoma incidence J:173575
increased liver adenocarcinoma incidence J:173575
increased skin papilloma incidence J:173575
increased tumor incidence J:173575
Auts2em1(IMPC)Wtsi/Auts2em1(IMPC)Wtsi
(C57BL/6N-Auts2em1(IMPC)Wtsi/Wtsi)
embryo tumor J:239583
B2mtm1Unc/B2mtm1Unc
Il2tm1Hor/Il2tm1Hor

(involves: 129 * C57BL/6)
increased intestinal adenocarcinoma incidence J:51450
B2mtm1Unc/B2mtm1Unc
Prkdcscid/Prkdcscid

(NOD.Cg-B2mtm1Unc Prkdcscid)
increased T cell derived lymphoma incidence J:102141
B3gnt6tm1Lx/B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J)
increased adenocarcinoma incidence J:123826
increased carcinoma incidence J:123826
increased gastrointestinal tumor incidence J:123826
increased incidence of tumors by chemical induction J:123826
increased intestinal adenoma incidence J:123826
increased tumor growth/size J:123826
B3gnt6tm1Lx/B3gnt6tm1Lx
C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc
Tg(Vil1-cre)997Gum/0

(involves: 129S1/Sv * C57BL/6J * SJL)
increased duodenum glandular epithelium tumor incidence J:239765
B3gnt6tm1Lx/B3gnt6tm1Lx
C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc
Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2)
increased duodenum adenocarcinoma incidence J:239765
increased duodenum glandular epithelium tumor incidence J:239765
B9d2tm1a(EUCOMM)Wtsi/B9d2tm1a(EUCOMM)Wtsi
(C57BL/6N-B9d2tm1a(EUCOMM)Wtsi/Wtsi)
embryo tumor J:239583
Badtm1Sjk/Badtm1Sjk
(either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))
increased B cell derived lymphoma incidence J:84987
increased lymphoma incidence J:84987
increased tumor incidence J:84987
Bag1tm1Msd/Bag1+
Tg(SFTPC-RAF1-BxB)1Urr/0

(involves: C57BL/6)
decreased lung tumor incidence J:95491
Bak1tm1Thsn/Bak1tm1Thsn
Baxtm1Sjk/Baxtm2Sjk
Krastm4Tyj/Kras+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
increased adenocarcinoma incidence J:125101
Bap1em1Test/Bap1+
(involves: FVB)
increased colon tumor incidence J:231692
increased granulosa cell tumor incidence J:231692
increased incidence of tumors by chemical induction J:213725
increased lung carcinoma incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased mesothelioma incidence J:231692
increased ovary tumor incidence J:231692
increased skin tumor incidence J:231692
increased squamous cell carcinoma incidence J:213725
Bap1em2Test/Bap1+
(involves: FVB)
increased granulosa cell tumor incidence J:231692
increased incidence of tumors by chemical induction J:231692
increased lung carcinoma incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased mesothelioma incidence J:231692
increased ovary tumor incidence J:231692
increased pancreatic islet cell carcinoma incidence J:231692
increased skin tumor incidence J:231692
Bap1em3Test/Bap1+
(involves: FVB)
increased granulosa cell tumor incidence J:231692
increased incidence of tumors by chemical induction J:231692
increased lung carcinoma incidence J:231692
increased lymphoma incidence J:231692
increased mammary adenocarcinoma incidence J:231692
increased ovary tumor incidence J:231692
increased skin tumor incidence J:231692
Bap1tm1.1Geno/Bap1tm1.1Geno
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+

(involves: C57BL/6 * C57BL/6NTac)
increased leukemia incidence J:187380
Bard1tm1Thl/Bard1tm2Thl
Waptm1(cre)Arge/0

(involves: 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Bard1tm2Thl/Bard1tm2Thl
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0

(involves: 129/Sv * 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Bard1tm2Thl/Bard1tm2Thl
Waptm1(cre)Arge/0

(involves: 129/Sv * 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Bcl2tm1Mpin/Bcl2+
Tg(SFTPC-RAF1-BxB)1Urr/0

(involves: 129S2/SvPas * C57BL/6 * DBA/2)
increased lung adenoma incidence J:79696
Bcl2tm1Mpin/Bcl2tm1Mpin
Tg(H2-K-BCL2)1Josd/0
Tg(SFTPC-RAF1-BxB)1Urr/0

(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2)
increased lung adenoma incidence J:79696
Bcl2tm1Mpin/Bcl2tm1Mpin
Tg(SFTPC-RAF1-BxB)1Urr/0

(involves: 129S2/SvPas * C57BL/6 * DBA/2)
decreased tumor incidence J:79696
increased lung adenoma incidence J:79696
Bcl2tm2.1Lbox/Bcl2+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased B cell derived lymphoma incidence J:175730
increased follicular lymphoma incidence J:175730
Bcl2tm2.1Lbox/Bcl2tm2.1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased B cell derived lymphoma incidence J:175730
increased follicular lymphoma incidence J:175730
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam
Tg(Ins2-cre)25Mgn/0
Tg(RIP1-Tag)2Dh/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA)
increased pancreas tumor incidence J:146436
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam
Tg(RIP1-Tag)2Dh/0

(involves: 129S6/SvEvTac * C57BL/6 * DBA)
increased pancreas tumor incidence J:146436
Bcl2l11tm1.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:186117
increased T cell derived lymphoma incidence J:186117
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:186117
Bcl2l11tm2.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:186117
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:186117
Bcl2l11tm3.1Boui/Bcl2l11+
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:186117
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui
Tg(IghMyc)22Bri/0

(involves: C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:186117
Bcl11btm1Peli/Bcl11btm1Peli
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6J)
decreased metastatic potential J:161373
Bcl11btm2Jpk/Bcl11b+
Tg(Lck-cre)1Jtak/0

(involves: C57BL/6)
increased lymphoma incidence J:210122
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J)
increased follicular lymphoma incidence J:86953
increased hepatocellular carcinoma incidence J:86953
increased histiocytic sarcoma incidence J:86953
increased lung adenocarcinoma incidence J:86953
increased lung adenoma incidence J:86953
increased lung carcinoma incidence J:86953
increased lymphoma incidence J:86953
increased malignant tumor incidence J:86953
increased mammary gland tumor incidence J:86953
increased plasmacytoma incidence J:86953
increased tumor incidence J:86953
Becn1tm1Blev/Becn1+
Tg(Alb1HBV)44Bri/0

(involves: 129X1/SvJ * C57BL/6J)
increased tumor incidence J:86953
Becn1tm1Htz/Becn1+
(involves: 129P2/OlaHsd * C57BL/6)
increased B cell derived lymphoma incidence J:86982
increased hepatocellular carcinoma incidence J:86982
increased lung adenocarcinoma incidence J:86982
increased tumor incidence J:86982
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6)
increased hepatocellular carcinoma incidence J:105076
increased liver adenoma incidence J:105076
increased pancreas adenoma incidence J:105076
increased pancreatic acinar cell carcinoma incidence J:105076
increased tumor incidence J:105076
Bhlha15tm2(Kras)Skz/Bhlha15+
Trp53tm1Tyj/Trp53+

(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
increased hepatocellular carcinoma incidence J:105076
increased metastatic potential J:105076
Bhmttm1.2Zei/Bhmttm1.2Zei
(involves: 129P2/OlaHsd * C57BL/6)
increased hepatocellular carcinoma incidence J:177569
increased liver adenoma incidence J:177569
increased liver tumor incidence J:177569
Bin1tm1Gcp/Bin1tm2Gcp
Tg(MMTV-Myc)141-3Led/0
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
increased lymphoma incidence J:117330
increased mammary adenocarcinoma incidence J:117330
Bin1tm1Gcp/Bin1tm2Gcp
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
increased granulosa cell tumor incidence J:117330
increased incidence of tumors by chemical induction J:117330
increased mammary gland tumor incidence J:117330
Bin1tm2Gcp/Bin1+
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
increased incidence of tumors by chemical induction J:117330
increased mammary gland tumor incidence J:117330
Bin3tm1Gcp/Bin3tm1Gcp
(involves: 129 * C57BL/6)
increased incidence of tumors by ionizing radiation induction J:133313
increased lung adenocarcinoma incidence J:133313
increased lymphoma incidence J:133313
Blmtm1Ches/Blmtm3Brd
(involves: 129S/SvEv * C57BL/6 * NIH Black Swiss)
increased lymphoma incidence J:86827
increased tumor incidence J:86827
Blmtm1Ches/Blmtm4Ches
Tg(Hsp70-1-cre)6Arge/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA)
increased mammary gland tumor incidence J:112115
Blmtm1Ches/Blmtm4Ches
Tg(KLK3-cre)1Ches/0

(involves: 129S6/SvEvTac)
increased mammary gland tumor incidence J:112115
Blmtm1Ches/Blmtm4Ches
Tg(LGB-cre)74Acl/0

(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
increased mammary adenocarcinoma incidence J:112115
Blmtm1Grdn/Blm+
(involves: 129P2/OlaHsd * Black Swiss)
increased incidence of induced tumors J:79058
Blmtm3Brd/Blmtm3Brd
(involves: 129S7/SvEvBrd * C57BL/6)
increased lymphoma incidence J:66261
increased tumor incidence J:66261
Blnktm1Dkit/Blnktm1Dkit
(involves: C57BL/6)
increased leukemia incidence J:84040
Blnktm1Dkit/Blnktm1Dkit
Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn

(involves: 129P2/OlaHsd * C57BL/6 * NZB)
increased leukemia incidence J:84040
Blnktm1Pjln/Blnktm1Pjln
(involves: BALB/c)
increased tumor incidence J:80332
Blnktm1Pjln/Blnktm1Pjln
Btktm1Gsv/Y

(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
increased B cell derived lymphoma incidence J:94768
Blnktm1Pjln/Blnktm1Pjln
Btktm1Gsv/Y
Tg(CD19-BTK*K430R)XK24Rwhe/?

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * FVB)
neoplasm J:94768
Bmftm1.1Ast/Bmftm1.1Ast
(B6(C)-Bmftm1.1Anst)
increased T cell derived lymphoma incidence J:133084
neoplasm J:133084
Bmi1tm1(cre/ERT)Mrc/Bmi1+
Ctnnb1tm1Mmt/Ctnnb1+

(involves: 129S1/Sv * 129X1/SvJ)
increased intestinal adenoma incidence J:138364
Bmi1tm1.1Lees/Bmi1tm1.1Lees
Apctm2Cip/Apc+
Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2)
decreased alimentary system tumor incidence J:204354
decreased colon tumor incidence J:204354
decreased intestinal adenoma incidence J:204354
Bmi1tm1Brn/Bmi1tm1Brn
Apctm2Cip/Apc+
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)
increased intestinal adenoma incidence J:204354
Bmi1tm1Brn/Bmi1tm1Brn
Apctm2Cip/Apc+
Tg(Vil1-cre)20Syr/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
decreased alimentary system tumor incidence J:204354
decreased colon tumor incidence J:204354
decreased intestinal adenoma incidence J:204354
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr
Ctnnb1tm1Mmt/Ctnnb1+
Krt14tm1.1(cre)Wbm/Krt14+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ)
increased salivary gland tumor incidence J:199091
increased squamous cell carcinoma incidence J:199091
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr
Krt14tm1.1(cre)Wbm/Krt14+

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
neoplasm J:199091
Bmpr1atm2Bhr/Bmpr1atm2Bhr
Tg(KRT14-cre/ERT2)1Ipc/?

(involves: 129S7/SvEvBrd * C57BL/6)
preneoplasia J:91054
Bmyctm1Mpo/Bmyctm1Mpo
(involves: 129S7/SvEvBrd * C57BL/6N)
neoplasm J:191587
Boktm1.1Ast/Boktm1.1Ast
Tg(IghMyc)22Bri/0

(involves: BALB/cJ * C57BL * C57BL/6 * SJL)
increased lymphoma incidence J:203179
Bomb1NSF/N/Bomb1NSF/N
(involves: NFS/N * SL/Kh)
increased lymphoma incidence J:55364
Bomb1SL/Kh/Bomb1SL/Kh
(involves: NFS/N * SL/Kh)
increased lymphoma incidence J:55364
Braftm1.1Brd/Braf+
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Tg(Vil1-cre)997Gum/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
increased carcinoma incidence J:199307
increased intestinal adenoma incidence J:199307
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0

(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
increased carcinoma incidence J:199307
increased gastrointestinal tumor incidence J:199307
increased intestinal adenoma incidence J:199307
Braftm1.1Brd/Braf+
Tg(Vil1-cre)997Gum/0
Trp53tm2Tyj/Trp53tm2Tyj

(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6 * SJL)
altered tumor pathology J:199307
increased metastatic potential J:199307
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
increased gland tumor incidence J:170095
increased lung adenoma incidence J:170095
increased metastatic potential J:170095
increased pheochromocytoma incidence J:170095
Braftm1Cpri/Braf+
(involves: 129P2/OlaHsd)
increased lung adenoma incidence J:187371
increased lung tumor incidence J:187371
Braftm1Cpri/Braf+
Tg(Mx1-cre)1Cgn/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased leukemia incidence J:104375
Braftm1Cpri/Braftm1Cpri
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-cre/ERT2)1Lru/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
increased incidence of tumors by chemical induction J:147434
increased melanoma incidence J:147434
increased skin tumor incidence J:147434
Braftm1Cpri/Braftm1Cpri
Gnastm3Lsw/Gnastm3Lsw
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/NCr)
increased thyroid tumor incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * FVB/NCr)
increased thyroid carcinoma incidence J:168249
increased thyroid tumor incidence J:168249
Braftm1Cpri/Braftm1Cpri
Tg(Tyr-cre/ERT2)1Lru/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased melanoma incidence J:147434
increased skin tumor incidence J:147434
Braftm1Cpri/Braftm1Cpri
Tshrtm1Rmar/Tshrtm1Rmar
Tg(TPO-cre)1Shk/0

(involves: 129P2/OlaHsd * 129S1/Sv * FVB/NCr)
increased thyroid tumor incidence J:168249
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd)
increased lung adenocarcinoma incidence J:121715
increased lung adenoma incidence J:121715
increased lung tumor incidence J:121715
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Cdkn2atm4Rdp/Cdkn2atm4Rdp

(involves: 129P2/OlaHsd)
increased lung tumor incidence J:121715
Braftm1Mmcm/Braf+
Polr2atm1(cre/ERT2)Bbd/Polr2a+

(involves: 129P2/OlaHsd * C57BL/6 * SJL)
increased lung adenoma incidence J:121715
Braftm1Mmcm/Braf+
Ptentm1Mro/Ptentm1Mro
Tg(Tyr-cre/ERT2)1Lru/0

(B6.Cg-Braftm1Mmcm Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru)
increased cutaneous melanoma incidence J:188523
Braftm1Mmcm/Braf+
Ptentm1Rdp/Ptentm1Rdp
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
increased cutaneous melanoma incidence J:151023
increased metastatic potential J:151023
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Pten+
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
increased cutaneous melanoma incidence J:151023
Braftm1Mmcm/Braf+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
increased cutaneous melanoma incidence J:151023
increased metastatic potential J:151023
Braftm1Mmcm/Braf+
Tg(Tg-cre/ERT2)#Mmcm/0

(involves: 129P2/OlaHsd)
increased thyroid carcinoma incidence J:172205
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Tg(TPO-cre/ERT2)1139Tyj/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased metastatic potential J:208854
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd)
increased lung adenocarcinoma incidence J:121715
increased lung tumor incidence J:121715
Braftm1Mmcm/Braf+
Trp53tm1Brn/Trp53tm3.1Tyj
Tg(TPO-cre/ERT2)1139Tyj/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braf+
Trp53tm3.1Tyj/Trp53+
Tg(TPO-cre/ERT2)1139Tyj/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
increased thyroid carcinoma incidence J:208854
Braftm1Mmcm/Braftm1Mmcm
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+
Ptentm1Hwu/Pten+

(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
increased metastatic potential J:191327
increased prostate gland adenocarcinoma incidence J:191327
increased prostate gland tumor incidence J:191327
increased prostate intraepithelial neoplasia incidence J:191327
Braftm1Rima/Braf+
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)1Lru/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased tumor incidence J:161180
Braftm1Rima/Braf+
Tg(GFP/KRAS2/ALPP)1Brn/0
Tg(Tyr-cre/ERT2)1Lru/0

(involves: C57BL/6 * DBA/2 * FVB/N)
increased melanoma incidence J:161180
Braftm1Rima/Braf+
Tg(Tyr-cre/ERT2)1Lru/0

(involves: C57BL/6 * DBA/2)
neoplasm J:161180
Braftm1Sva/Braftm1Sva
Krastm1Bbd/Kras+

(involves: 129S1/Sv * 129X1/SvJ)
increased lung non-small cell carcinoma incidence J:172200
Braftm1Tuv/Braftm1Tuv
Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+
Tg(Tyr-cre/ERT2)13Bos/0
TgTn(sb-T2/Onc)#Dla/0

(involves: 129S6/SvEvTac * FVB/N)
increased melanoma incidence J:177503
Braftm2Cpri/Braf+
Krastm4Tyj/Kras+

(involves: 129S4/SvJae * C57BL/6)
increased lung adenoma incidence J:187371
Braftm2Cpri/Braf+
Tg(CMV-cre)1Cgn/0

(B6.Cg-Braftm2Cpri Tg(CMV-cre)1Cgn)
increased intestinal adenoma incidence J:187371
increased skin papilloma incidence J:187371
Brca1tm1Aash/Brca1tm1Aash
Tg(LGB-cre)74Acl/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
increased mammary gland tumor incidence J:119996
increased salivary adenocarcinoma incidence J:119996
Brca1tm1Aash/Brca1tm1Aash
Trp53tm1Brd/Trp53+
Tg(LGB-cre)74Acl/0

(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
increased mammary gland ductal carcinoma incidence J:119996
increased mammary gland tumor incidence J:119996
increased salivary adenocarcinoma incidence J:119996
Brca1tm1Arge/Brca1tm1Thl
Waptm1(cre)Arge/0

(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Brca1tm1Bhk/Brca1+
(C.129P2-Brca1tm1Bhk)
increased mammary gland tumor incidence J:198018
Brca1tm1Bhk/Brca1+
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi

(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk)
increased mammary adenocarcinoma incidence J:198018
increased mammary gland tumor incidence J:198018
increased metastatic potential J:198018
Brca1tm1Brn/Brca1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
increased mammary gland tumor incidence J:126551
Brca1tm1Brn/Brca1tm1.1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
abnormal tumor morphology J:178595
altered tumor pathology J:178595
decreased mammary gland tumor incidence J:178595
decreased skin tumor incidence J:178595
decreased tumor latency J:178595
Brca1tm1Brn/Brca1tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
neoplasm J:126551
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
increased ovary tumor incidence J:189304
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
increased carcinoma incidence J:189304
increased metastatic potential J:189304
increased ovarian carcinoma incidence J:189304
increased ovary tumor incidence J:189304
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
increased mammary gland tumor incidence J:126551
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
increased mammary gland tumor incidence J:126551
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
abnormal tumor morphology J:178595
altered tumor pathology J:178595
increased mammary gland tumor incidence J:178595
increased skin tumor incidence J:178595
increased tumor latency J:178595
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-cre)5132Jlj/0

(involves: 129S6/SvEvTac * C57BL/6)
increased mouth tumor incidence J:85354
increased skin tumor incidence J:85354
increased squamous cell carcinoma incidence J:85354
increased tumor incidence J:85354
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-cre)5132Jlj/0
Tg(KRT5-E2F1)2Dgj/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
decreased tumor latency J:85354
increased skin tumor incidence J:85354
increased squamous cell carcinoma incidence J:85354
Brca1tm1Cxd/Brca1tm2Cxd
Tg(KRT5-E2F1)2Dgj/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
increased mouth tumor incidence J:85354
increased papilloma incidence J:85354
increased reproductive system tumor incidence J:85354
increased skin tumor incidence J:85354
increased squamous cell carcinoma incidence J:85354
increased tumor incidence J:85354
Brca1tm1Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * Black Swiss * FVB)
increased mammary adenocarcinoma incidence J:54533
increased mammary gland tumor incidence J:54533
Brca1tm1Cxd/Brca1tm2Cxd
Tg(Wap-cre)11738Mam/0

(involves: 129S6/SvEvTac * Black Swiss)
increased mammary gland tumor incidence J:54533
Brca1tm1Cxd/Brca1tm2Cxd
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
increased mammary gland tumor incidence J:54533
Brca1tm1Thl/Brca1tm1Thl
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
decreased tumor latency J:177853
Brca1tm1Thl/Brca1tm1Thl
Waptm1(cre)Arge/0

(involves: 129S1/Sv * C57BL/6J)
increased mammary adenocarcinoma incidence J:134977
Brca1tm1Thl/Brca1tm2.1Thl
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
decreased tumor latency J:177853
Brca1tm1Thl/Brca1tm3.1Thl
Krastm4Tyj/Kras+
Trp53tm1Thl/Trp53tm1Thl
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
decreased tumor latency J:177853
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased carcinoma incidence J:122899
increased incidence of tumors by chemical induction J:122899
increased mammary gland tumor incidence J:70271
increased T cell derived lymphoma incidence J:81541
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
increased tumor incidence J:81559
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
increased T cell derived lymphoma incidence J:81541
Brca1tm2.1Cxd/Brca1tm2.1Cxd
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
decreased tumor latency J:177853
Brca1tm2.1Cxd/Brca1tm2.1Thl
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
decreased tumor latency J:177853
Brca1tm2.1Cxd/Brca1tm3.1Thl
Trp53tm3Tyj/Trp53+
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
increased tumor latency J:177853
Brca1tm2.1Cxd/Brca1tm3.1Thl
Waptm1(cre)Arge/Wap+

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
neoplasm J:177853
Brca1tm2.1Thl/Brca1tm2.1Thl
(involves: 129 * C57BL/6)
increased tumor incidence J:177853
Brca1tm2.1Thl/Brca1tm2.1Thl
(involves: 129)
increased tumor incidence J:197743
Brca1tm2Arge/Brca1tm2Arge
(129-Brca1tm2Arge)
increased mammary gland tumor incidence J:69187
increased tumor incidence J:69187
Brca1tm2Arge/Brca1tm2Arge
(involves: 129/Sv * C57BL/6J * MF1)
increased mammary gland tumor incidence J:69187
increased tumor incidence J:69187
Brca1tm2Arge/Brca1tm2Arge
(involves: 129 * C57BL/6)
increased tumor incidence J:177853
Brca1tm2Arge/Brca1tm3.1Thl
(involves: 129 * C57BL/6)
neoplasm J:177853
Brca1tm2Cxd/Brca1+
Tg(KRT5-E2F1)2Dgj/0

(involves: 129S6/SvEvTac * C57BL/6 * SJL)
increased skin tumor incidence J:85354
increased squamous cell carcinoma incidence J:85354
increased tumor incidence J:85354
Brca1tm2Cxd/Brca1tm2Cxd
Pkmtm1.1Mgvh/Pkmtm1.1Mgvh
Trp53tm1Brd/Trp53+
Tg(MMTV-cre)4Mam/0

(involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N)
increased liver tumor incidence J:205213
increased mammary gland tumor incidence J:205213
increased metastatic potential J:205213
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB)
increased mammary gland tumor incidence J:132088
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Tg(MMTV-rtTA)1Lach/0
Tg(tetO-Esr1)#Paf/0
Trp53tm1Brd/Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
increased mammary gland tumor incidence J:132088
preneoplasia J:132088
Brca1tm2Cxd/Brca1tm2Cxd
Tg(MMTV-cre)4Mam/0
Trp53tm1Brd/Trp53+

(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
increased mammary gland tumor incidence J:132088
preneoplasia J:132088
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Chek2tm1Mak/Chek2tm1Mak
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased mammary adenocarcinoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased tumor incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Tg(Lck-cre)548Jxm/?
Trp53tm1Brd/Trp53tm1Brd

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
increased T cell derived lymphoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased mammary gland tumor incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53+
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased mammary adenocarcinoma incidence J:90512
Brca1tm2Mak/Brca1tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Wap-cre)11738Mam/?

(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
increased tumor incidence J:90512
Brca1tm3.1Thl/Brca1tm3.1Thl
(involves: 129 * C57BL/6)
neoplasm J:177853
Brca1tm3Cxd/Brca1tm3Cxd
(involves: 129S6/SvEvTac * FVB/N)
increased hepatoma incidence J:94114
increased incidence of tumors by ionizing radiation induction J:94114
increased lipoma incidence J:94114
increased lymphoma incidence J:94114
increased mammary gland tumor incidence J:94114
increased tumor incidence J:94114
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
increased mammary gland ductal carcinoma incidence J:112308
increased mammary gland tumor incidence J:112308
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
increased incidence of tumors by ionizing radiation induction J:155810
increased liver tumor incidence J:155810
increased lymphoma incidence J:155810
increased mammary gland tumor incidence J:155810
increased T cell derived lymphoma incidence J:155810
Brca2tm1Arge/Brca2+
(involves: 129S/SvEv * C57BL/6)
neoplasm J:40594
Brca2tm1Arge/Brca2tm2Arge
Waptm1(cre)Arge/Wap+

(involves: 129S/SvEv * C57BL/6)
increased mammary adenocarcinoma incidence J:70564
Brca2tm1Brn/Brca2+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:73028
increased mammary gland tumor incidence J:73028
increased skin tumor incidence J:73028
increased tumor incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0

(involves: 129 * C57BL/6 * SJL)
increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Brn
Ptch1tm1Mps/Ptch1+
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0

(involves: 129 * C57BL/6 * SJL)
increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
increased ovary tumor incidence J:189304
Brca2tm1Brn/Brca2tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:161511
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:73028
increased mammary gland tumor incidence J:73028
increased skin tumor incidence J:73028
increased tumor incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53+
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:161511
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:73028
increased mammary gland tumor incidence J:73028
increased skin tumor incidence J:73028
increased tumor incidence J:73028
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(Pbsn-cre)4Prb/0

(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
increased prostate intraepithelial neoplasia incidence J:161511
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53+
Tg(Nes-cre)1Kln/0

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
abnormal tumor morphology J:144617
increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Brn
Trp53tm1Tyj/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
increased medulloblastoma incidence J:144617
Brca2tm1Brn/Brca2tm1Cam
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic acinar cell carcinoma incidence J:166678
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2+
Krastm4Tyj/Kras+
Trp53tm3Tyj/Trp53+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2tm1Brn
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:166678
Brca2tm1Cam/Brca2tm1Brn
Tg(Pdx1-cre)6Tuv/0
Trp53tm3Tyj/Trp53+

(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
increased malignant tumor incidence J:166678
increased sarcoma incidence J:166678
Brca2tm1Cam/Brca2tm1Cam
(involves: 129S/SvEv * MF1)
increased T cell derived lymphoma incidence J:46812
Brca2tm1Cbl/Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))
increased T cell derived lymphoma incidence J:44386
Brca2tm1Hst/Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6)
decreased tumor latency J:82434
increased carcinoma incidence J:82434
increased lymphoma incidence J:82434
Brca2tm1Kamc/Brca2tm1Kamc
(involves: 129P2/OlaHsd * C57BL/6N)
increased tumor incidence J:75026
neoplasm J:109193
Brca2tm1Kamc/Brca2tm1Kamc
Trp53tm1Tyj/Trp53+

(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
increased mammary gland tumor incidence J:109193
increased osteosarcoma incidence J:109193
increased stomach tumor incidence J:109193
Brca2tm1Mak/Brca2tm2Mak
Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * C57BL/6 * CBA)
neoplasm J:79697
Brca2tm1Mak/Brca2tm2Mak
Trp53tm1Brd/Trp53tm1Brd
Tg(Lck-cre)548Jxm/0

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
increased lymphoma incidence J:79697
increased malignant tumor incidence J:79697
increased osteosarcoma incidence J:79697
increased tumor incidence J:79697
Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
increased mammary gland tumor incidence J:67445
Brca2tm1Mhun/Brca2+
(involves: 129S7/SvEvBrd * C57BL/6J)
decreased incidence of tumors by chemical induction J:89083
decreased tumor incidence J:89083
Brca2tm2Arge/Brca2tm2Arge
Waptm1(cre)Arge/Waptm1(cre)Arge

(involves: 129S1/Sv * C57BL/6)
increased mammary adenocarcinoma incidence J:70564
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd)
increased adenocarcinoma incidence J:227115
increased adenoma incidence J:227115
increased Harderian gland adenoma incidence J:227115
increased lymphoma incidence J:227115
increased pituitary adenoma incidence J:227115
increased tumor incidence J:227115
Btg3tm1Tya/Btg3tm1Tya
(involves: 129P2/OlaHsd * C57BL/6J)
increased lung adenoma incidence J:149382
increased lung carcinoma incidence J:149382
increased lung tumor incidence J:149382
Btrctm1Kin/Btrctm1Kin
(involves: C57BL/6)
neoplasm J:84639
Bts1C57BL/6JShi/?
(involves: C57BL/6JShi * NON/Shi)
decreased incidence of tumors by chemical induction J:51984
Bts1NON/Shi/?
(involves: C57BL/6JShi * NON/Shi)
increased tumor incidence J:51984
Bts2C57BL/6JShi/?
(involves: C57BL/6JShi * NON/Shi)
decreased incidence of tumors by chemical induction J:51984
Bts2NON/Shi/?
(involves: C57BL/6JShi * NON/Shi)
increased tumor incidence J:51984
Bub1tm1.1Jvd/Bub1+
(involves: 129/Sv * C57BL/6)
decreased tumor incidence J:135093
increased incidence of tumors by chemical induction J:135093
Bub1tm1.1Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
decreased tumor latency J:135093
increased lung tumor incidence J:135093
increased lymphoma incidence J:135093
increased sarcoma incidence J:135093
Bub1tm1.1Tvd/Bub1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
increased brain tumor incidence J:143035
increased lung tumor incidence J:143035
Bub1tm1.1Tvd/Bub1tm1.1Tvd
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
increased incidence of induced tumors J:143035
increased liver tumor incidence J:143035
increased lung tumor incidence J:143035
Bub1tm2Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
decreased tumor latency J:135093
increased hepatocellular carcinoma incidence J:135093
increased sarcoma incidence J:135093
Bub1tm3.1Jvd/Bub1tm3.1Jvd
(involves: 129S4/SvJae * C57BL/6)
neoplasm J:195237
Bub1bGt(neo-btk)1Dai/Bub1b+
(involves: 129S4/SvJae)
increased colon adenoma incidence J:88094
increased intestinal adenocarcinoma incidence J:88094
Bub1btm1.1Hsl/Bub1b+
(involves: 129 * C57BL/6)
increased adenocarcinoma incidence J:201641
increased B cell derived lymphoma incidence J:201641
increased fibrosarcoma incidence J:201641
increased hemangiosarcoma incidence J:201641
increased hepatocellular carcinoma incidence J:201641
increased incidence of induced tumors J:201641
increased leukemia incidence J:201641
increased lung adenocarcinoma incidence J:201641
increased lymphoma incidence J:201641
increased rectum adenocarcinoma incidence J:201641
increased sarcoma incidence J:201641
Bub1btm2.1Jvd/Bub1b+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
increased tumor growth/size J:194926
neoplasm J:194926
Bub3tm1Jvd/Bub3+
(Not Specified)
increased incidence of tumors by chemical induction J:81546
Bub3tm1Jvd/Bub3+
Rae1tm1Jvd/Rae1+

(Not Specified)
increased incidence of tumors by chemical induction J:81546
Cables1tm1Lrz/Cables1tm1Lrz
(involves: 129S1/Sv)
increased endometrial carcinoma incidence J:87478
Cacfd1tm1.1Geno/Cacfd1tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J)
decreased incidence of tumors by chemical induction J:184968
increased tumor latency J:184968
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn

(involves: 129 * 129P2/OlaHsd * FVB/N)
increased lung small cell carcinoma incidence J:190366
increased thyroid tumor incidence J:190366
Calcatm1.1(cre/ERT2)Ptch/Calca+
Trp53tm1Brn/Trp53tm1Brn
Rb1tm2Brn/Rb1tm2Brn
Ptentm1Hwu/Ptentm1Hwu

(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N)
increased lung small cell carcinoma incidence J:190366
increased metastatic potential J:190366
increased thyroid tumor incidence J:190366
Camk2gtm1.1Irt/Camk2gtm1.1Irt
(involves: C57BL/6J)
decreased incidence of tumors by chemical induction J:243363
Camta1tm1.2Eno/Camta1tm1.2Eno
(involves: C57BL/6)
neoplasm J:212232
Casc1Gt(VICTR21)709Lex/Casc1+
(involves: 129S5/SvEvBrd)
increased incidence of tumors by chemical induction J:111629
increased lung adenocarcinoma incidence J:111629
Casc1Gt(VICTR21)709Lex/Casc1Gt(VICTR21)709Lex
(involves: 129S5/SvEvBrd)
increased incidence of tumors by chemical induction J:111629
increased lung adenocarcinoma incidence J:111629
increased lung adenoma incidence J:111629
Casp1tm1Flv/Casp1tm1Flv
Casp4del/Casp4del

(involves: 129S2/SvPas)
decreased metastatic potential J:59893
decreased tumor growth/size J:59893
Casp1tm1Flv/Casp1tm1Flv
Casp4del/Casp4del

(involves: 129S2/SvPas * C57BL/6J)
decreased incidence of tumors by chemical induction J:191239
Casp1tm1Sesh/Casp1tm1Sesh
Casp4del/Casp4del

(involves: 129S2/SvPas * C57BL/6)
neoplasm J:22964, J:40691
Casp8tm1Clie/Casp8tm1Clie
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr
Tg(Alb1-cre)7Gsc/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
neoplasm J:218665
Casp12tm1Yuan/Casp12tm1Yuan
(involves: 129S4/SvJae * C57BL/6J)
neoplasm J:59337
Catb/Catb
(C3.Cg-Catb/Anl)
decreased mammary gland tumor incidence J:5971
increased hepatoma incidence J:154291
increased incidence of tumors by chemical induction J:5971
Cav1tm1.1Aia/Cav1tm1.1Aia
(involves: 129S7/SvEvBrd * C57BL/6J)
neoplasm J:174719
Cav1tm1.1Aia/Cav1tm1.1Aia
crsp/+

(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
neoplasm J:174719
Cav1tm1.1Aia/Cav1tm1.1Aia
crsp/crsp

(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
neoplasm J:174719
Cav1tm1.1Aia/Cav1tm1.1Aia
Rxfp2tm1Aia/Rxfp2+

(involves: 129S7/SvEvBrd * C57BL/6J * FVB)
neoplasm J:174719
Cav1tm1Mls/Cav1+
Tg(MMTV-PyVT)634Mul/0

(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
increased mammary gland tumor incidence J:132472
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * SJL)
increased incidence of tumors by chemical induction J:83485
neoplasm J:109251
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
increased mammary gland tumor incidence J:147439
Cav1tm1Mls/Cav1tm1Mls
Tg(MMTV-PyVT)634Mul/0

(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
increased mammary gland tumor incidence J:132472
Cav1tm1Mls/Cav1tm1Mls
Tg(TRAMP)8247Ng/0

(involves: 129/Sv * C57BL/6 * SJL)
decreased tumor incidence J:133066
Cav2tm1(KOMP)Mbp/Cav2tm1(KOMP)Mbp
(C57BL/6N-Cav2tm1(KOMP)Mbp)
abnormal tumor morphology J:217189
abnormal tumor vascularization J:217189
altered tumor pathology J:217189
decreased tumor growth/size J:217189
tumor regression J:217189
Cbfbtm5Ppl/Cbfb+
(Not Specified)
neoplasm J:193140
Cbx7tm1Afus/Cbx7+
(involves: C57BL/6J)
increased hepatocellular carcinoma incidence J:184383
increased liver adenoma incidence J:184383
increased lung adenoma incidence J:184383
Cbx7tm1Afus/Cbx7tm1Afus
(involves: C57BL/6J)
increased carcinoma incidence J:184383
increased hepatocellular carcinoma incidence J:184383
increased liver adenoma incidence J:184383
increased liver tumor incidence J:184383
increased lung carcinoma incidence J:184383
increased lung tumor incidence J:184383
increased tumor incidence J:184383
Ccar2tm1Dac/Ccar2tm1Dac
(involves: 129 * C57BL/6J)
neoplasm J:228688
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6N)
increased hepatocellular carcinoma incidence J:216704
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified)
increased metastatic potential J:217742
increased ovarian carcinoma incidence J:217742
increased thyroid adenoma incidence J:217742
Ccl2tm1Rol/Ccl2tm1Rol
(involves: 129S4/SvJae * C57BL/6)
decreased incidence of tumors by chemical induction J:56068
Ccm2ltm1Mlkn/Ccm2ltm1Mlkn
(involves: 129 * C57BL/6)
abnormal tumor vascularization J:187714
decreased metastatic potential J:187714
decreased tumor growth/size J:187714
Ccnctm1.1Pisc/Ccnctm1.1Pisc
Tg(Lck-LMO1)11Sjk/0
Tg(Mx1-cre)1Cgn/0

(Not Specified)
increased T cell derived lymphoma incidence J:217695
Ccnctm1.1Pisc/Ccnctm1.1Pisc
Tg(Mx1-cre)1Cgn/0

(Not Specified)
neoplasm J:217695
Ccnd1tm1Dsn/Ccnd1tm1Dsn
Cdkn1btm1Mlf/Cdkn1btm1Mlf

(involves: 129 * C57BL/6)
increased pituitary adenoma incidence J:66707
Ccnd1tm1Phin/Ccnd1tm1Phin
Tg(MMTV-Erbb2)NK1Mul/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
decreased mammary gland tumor incidence J:105045
Ccnd1tm1Wbg/Ccnd1+
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
Ccnd1tm1Wbg/Ccnd1+
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Smarcb1tm1Gvk/Smarcb1+

(involves: 129/Sv * 129S2/SvPas * C57BL/6J * SJL/J)
decreased tumor incidence J:101185
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
increased tumor latency J:178842
Ccnd1tm1Wbg/Ccnd1tm1Wbg
Tg(MMTVneu)202Mul/0
Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0

(involves: 129S2/SvPas * FVB/N)
increased mammary gland tumor incidence J:178842
increased tumor latency J:178842
Ccnd1tm1Wbg/Ccnd1tm5.1Pisc
Tg(CAG-cre/Esr1*)5Amc/0
Tg(MMTV-Erbb2)NK1Mul/0

(involves: 129S2/SvPas * C57BL/6 * CBA * FVB/N)
decreased tumor growth/size J:192032
Ccnd1tm4Pisc/Ccnd1tm4Pisc
Tg(MMTV-Erbb2)NK1Mul/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:156591
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Tg(Lck)4220Rmp/0

(involves: C57BL/6J * DBA/2)
decreased lymphoma incidence J:88120
increased T cell derived lymphoma incidence J:88120
Ccnd3tm1Pisc/Ccnd3tm1Pisc
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S2/SvPas)
increased T cell derived lymphoma incidence J:88120
Ccndbp1tm1Riet/Ccndbp1tm1Riet
(involves: 129P2/OlaHsd * C57BL/6)
increased hepatocellular carcinoma incidence J:121623
increased liver adenoma incidence J:121623
Ccne1tm1Jro/?
Trp53tm1Tyj/Trp53tm1Tyj

(either: (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6J) or (involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6 * C57BL/6J))
decreased tumor latency J:99695
Ccng1tm1Sst/Ccng1tm1Sst
(involves: 129S/SvEv * C57BL/6)
decreased hepatoma incidence J:106007
decreased incidence of induced tumors J:106007
increased hepatoma incidence J:106007
Ccr2tm1Ifc/Ccr2tm1Ifc
(B6.129S4-Ccr2tm1Ifc/J)
decreased tumor growth/size J:122119
Ccr5tm1Kuz/Ccr5tm1Kuz
Tg(CAG-EGFP)1Osb/?

(involves: 129P2/OlaHsd * C3H * C57BL/6)
decreased metastatic potential J:97833
Ccs1C57BL/6Ha/?
(involves: C57BL/6Ha * ICR/Ha)
decreased tumor incidence J:19675
Ccs1ICR/Ha/?
(involves: C57BL/6Ha * ICR/Ha)
increased tumor incidence J:19675
Cd1tm1Gru/Cd1tm1Gru
(involves: 129S2/SvPas * BALB/c)
decreased metastatic potential J:118828
Cd3etm1Mal/Cd3etm1Mal
Tg(Tcrb-TCF3/PBX1)23Gusa/0

(involves: C3H * C57BL/6 * C57BL/6J)
increased acute lymphoblastic leukemia incidence J:95693
increased leukemia incidence J:95693
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
increased T cell derived lymphoma incidence J:160931
Cd19tm1(cre)Cgn/Cd19+
Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+

(involves: 129P2/OlaHsd)
increased B cell derived lymphoma incidence J:228288
Cd19tm1(cre)Cgn/Cd19+
Inpp5dtm1Rav/Inpp5dtm1Rav
Ptentm1Hwu/Ptentm1Hwu

(involves: 129P2/OlaHsd * 129S4/SvJae)
increased follicular lymphoma incidence J:166155
increased lymphoma incidence J:166155
increased malignant tumor incidence J:166155
increased plasmacytoma incidence J:166155
increased splenic marginal zone lymphoma incidence J:166155
Cd19tm1(cre)Cgn/Cd19+
Mirc30tm1.1Rdf/Mirc30tm1.1Rdf

(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
increased B cell derived lymphoma incidence J:156946
increased leukemia incidence J:156946
Cd19tm1(cre)Cgn/Cd19+
Ptpn11tm1Ckq/Ptpn11+

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
increased acute lymphoblastic leukemia incidence J:177285
increased B cell derived lymphoma incidence J:177285
Cd19tm1(cre)Cgn/Cd19+
Trp53tm1Yjc/Trp53tm1Yjc

(involves: 129P2/OlaHsd * 129S1/Sv * BALB/c * C57BL/6)
neoplasm J:195018
Cd28tm1Mak/Cd28tm1Mak
Rc3h1san/Rc3h1+

(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)
decreased lymphoma incidence J:189087
increased T cell derived lymphoma incidence J:189087
Cd34tm1Szk/Cd34tm1Szk
(involves: 129P2/OlaHsd * C57BL/6J)
decreased incidence of tumors by chemical induction J:121305
increased skin papilloma incidence J:121305
Cd44tm1Mak/Cd44tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
decreased tumor growth/size J:110162
Cd44tm1Mak/Cd44tm1Mak
Tg(MMTV-PyVT)634Mul/0

(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
increased metastatic potential J:100774
Cd44tm1Mak/Cd44tm1Mak
Tg(MMTV-PyVT)634Mul/0

(B6.Cg-Cd44tm1Mak Tg(MMTV-PyVT)634Mul)
increased metastatic potential J:100774
Cd44tm1Mak/Cd44tm1Mak
Trp53tm1Tyj/Trp53+

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J)
decreased metastatic potential J:76201
increased lymphoma incidence J:76201
Cd47tm1Fpl/Cd47tm1Fpl
(involves: 129S7/SvEvBrd * C57BL/6)
decreased tumor incidence J:147367
Cd79atm1(cre)Reth/Cd79a+
Dynll1tm1.1Jhh/Dynll1tm1.1Jhh
Tg(IghMyc)22Bri/0

(B6.Cg-Dynll1tm1.1Jhh Cd79atm1(Cre)Reth Tg(IghMyc)22Bri)
decreased lymphoma incidence J:230105
Cd79atm1(cre)Reth/Cd79a+
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu

(involves: 129P2/OlaHsd * BALB/c * C57BL/6 * SJL)
neoplasm J:209928
Cd82tm1.1Xaz/Cd82tm1.1Xaz
(B6NCr.Cg-Cd82tm1.1Xaz)
abnormal tumor vascularization J:234155
Cd96tm1.1Mjs/Cd96tm1.1Mjs
(B6.129P2(Cg)-Cd96tm1.1Mjs)
altered tumor susceptibility J:209990
Cd151tm1Mhe/Cd151tm1Mhe
(B6.129S-Cd151tm1Mhe)
decreased incidence of induced tumors J:141595
Cd151tm2Nki/Cd151tm2Nki
Itga3tm1Son/Itga3+
Krt14tm1(cre)Wbm/?

(FVB.129P2-Cd151tm2Nki Itga3tm1Son Krt14tm1(cre)Wbm)
decreased incidence of tumors by chemical induction J:205736
decreased tumor growth/size J:205736
Cd151tm2Nki/Cd151tm2Nki
Krt14tm1(cre)Wbm/?

(FVB.129P2-Cd151tm2Nki Krt14tm1(cre)Wbm)
decreased incidence of tumors by chemical induction J:205736
decreased tumor growth/size J:205736
Cd160tm1Yxf/Cd160tm1Yxf
(C57BL/6-Cd160tm1Yxf)
increased tumor growth/size J:222131
Cd160tm1Yxf/Cd160tm1Yxf
Rag1tm1Mom/Rag1tm1Mom

(B6.Cg-Rag1tm1Mom Cd160tm1Yxf)
increased tumor growth/size J:222131
Cd226tm1.1Cln/Cd226tm1.1Cln
(B6.129P2-Cd226tm1.1Cln)
altered tumor susceptibility J:209990
increased metastatic potential J:159749
increased tumor growth/size J:159749
Cd226tm1Shib/Cd226tm1Shib
(involves: BALB/c)
increased incidence of induced tumors J:165704
increased incidence of tumors by chemical induction J:165704
Cd248tm1Huso/Cd248tm1Huso
(involves: 129S/SvEv * C57BL/6)
decreased tumor growth/size J:107172
Cdc20tm1.1Mama/Cdc20tm1.2Mama
Polr2atm1(cre/ERT2)Bbd/Polr2a+

(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL)
decreased tumor growth/size J:167609
tumor regression J:167609
Cdc20tm1.1Pzg/Cdc20+
(involves: 129S7/SvEvBrd * C57BL/6)
increased hepatoma incidence J:150421
increased lymphoma incidence J:150421
increased tumor incidence J:150421
Cdc25atm1Dvb/Cdc25atm1Dvb
(involves: 129)
increased incidence of tumors by ionizing radiation induction J:144548
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-Erbb2)NK1Mul/?

(involves: 129/Sv * C57BL/6 * FVB/N)
decreased incidence of induced tumors J:123144
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-Myc)141-3Led/?

(involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1)
neoplasm J:123144
Cdc25atm1Kiyo/Cdc25a+
Tg(MMTV-vHaras)SH1Led/?

(involves: 129/Sv * C57BL/6 * C57BL/6J * CD-1)
decreased incidence of induced tumors J:123144
Cdc73Gt(RRE190)Byg/Cdc73+
(B6.129P2-Cdc73Gt(RRE190)Byg)
increased parathyroid adenoma incidence J:243366
increased parathyroid gland tumor incidence J:243366
increased uterus tumor incidence J:243366
Cdc73tm1Btt/Cdc73+
Tg(PTH-cre)4167Slib/0

(Not Specified)
increased parathyroid adenoma incidence J:243366
increased parathyroid gland tumor incidence J:243366
Cdc73tm1Btt/Cdc73tm1Btt
Tg(PTH-cre)4167Slib/0

(Not Specified)
increased parathyroid adenoma incidence J:243366
increased parathyroid gland tumor incidence J:243366
Cdcp1tm1.2Moas/Cdcp1+
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
increased tumor incidence J:194368
Cdcp1tm1.2Moas/Cdcp1tm1.2Moas
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+
Tg(KRT14-cre/ERT)20Efu/0

(involves: 129X1/SvJ * C57BL/6 * CD-1 * FVB/N * SJL)
increased tumor growth/size J:194368
increased tumor incidence J:194368
Cdcp1tm1.2Moas/Cdcp1tm1.2Moas
Tg(MMTV-PyVT)634Mul/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
increased tumor growth/size J:194368
increased tumor incidence J:194368
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:116152
increased pilomatricoma incidence J:116152
increased skin tumor incidence J:116152
increased squamous cell carcinoma incidence J:116152
Cdh1tm1Jjon/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary adenocarcinoma incidence J:171765
increased mammary gland tumor incidence J:171765
Cdh1tm1Jjon/Cdh1tm1Jjon
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
neoplasm J:171765
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
abnormal tumor vascularization J:116152
increased mammary adenocarcinoma incidence J:116152
increased metastatic potential J:116152
increased skin tumor incidence J:116152
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53+
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary gland tumor incidence J:171765
increased metastatic potential J:171765
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0

(involves: 129P2/OlaHsd * FVB/N)
abnormal tumor vascularization J:116152
increased mammary adenocarcinoma incidence J:116152
increased metastatic potential J:116152
increased skin tumor incidence J:116152
Cdh1tm1Jjon/Cdh1tm1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(Wap-cre)51Nki/0

(involves: 129P2/OlaHsd * FVB/N)
increased mammary gland tumor incidence J:171765
increased metastatic potential J:171765
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)7Mul/0

(involves: 129 * C57BL/6 * FVB/N)
increased mammary adenocarcinoma incidence J:212549
increased metastatic potential J:212549
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0

(involves: 129 * C57BL/6 * FVB/N)
increased duodenum adenocarcinoma incidence J:212549
increased gastric adenocarcinoma incidence J:212549
increased metastatic potential J:212549
increased squamous cell carcinoma incidence J:212549
Cdh1tm2Kem/Cdh1+
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Vil1-cre)20Syr/0

(involves: 129 * C57BL/6 * DBA/2)
increased intestinal adenocarcinoma incidence J:212549
Cdh1tm2Kem/Cdh1+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
neoplasm J:212549
Cdh1tm2Kem/Cdh1tm2Kem
Smad4tm2.1Cxd/Smad4tm2.1Cxd
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)6Tuv/0

(involves: 129 * C57BL/6 * FVB/N)
increased gastric adenocarcinoma incidence J:212549
Cdh13tm1Brns/Cdh13tm1Brns
(Not Specified)
neoplasm J:132759
Cdh13tm1Brns/Cdh13tm1Brns
Tg(MMTV-PyVT)634Mul/0

(involves: C57BL/6 * FVB/N)
abnormal tumor morphology J:132759
abnormal tumor vascularization J:132759
decreased incidence of induced tumors J:132759
decreased tumor growth/size J:132759
increased mammary gland tumor incidence J:132759
increased metastatic potential J:132759
Cdk1tm2.1Kald/Cdk1tm2.1Kald
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+

(involves: 129 * C57BL/6 * DBA * SJL)
decreased incidence of induced tumors J:182141
Cdk1tm2.1Kald/Cdk1tm2.1Kald
Tg(CAG-cre/Esr1*)5Amc/0

(involves: 129 * C57BL/6 * CBA * SJL)
decreased tumor growth/size J:182141
Cdk2tm1Sgo/Cdk2tm1Sgo
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ)
decreased tumor incidence J:161780
Cdk2tm2Sgo/Cdk2tm2Sgo
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ)
decreased tumor incidence J:161780
Cdk4+/Cdk4+
Tg(Mt1-HGFSF)#Lmb/0

(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-HGFSF)#Lmb)
increased incidence of tumors by chemical induction J:111992
increased metastatic potential J:111992
increased skin tumor incidence J:111992
Cdk4tm1.1Bbd/Cdk4+
Krastm1Bbd/Kras+
Tg(CMV-cre)1Cgn/?

(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
increased hemangiosarcoma incidence J:86101
increased lung adenoma incidence J:86101
increased papilloma incidence J:86101
increased pituitary adenoma incidence J:86101
increased sarcoma incidence J:86101
Cdk4tm1.1Bbd/Cdk4+
Tg(Mt1-HGFSF)#Lmb/0

(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-HGFSF)#Lmb)
decreased tumor growth/size J:111992
increased incidence of tumors by chemical induction J:111992
increased metastatic potential J:111992
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
(B6.129(Cg)-Cdk4tm1.1Bbd)
neoplasm J:111992
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Krt14tm1(cre)Wbm/Krt14+
Pard3tm1Shoh/Pard3tm1Shoh
Tg(Mt1-HGFSF)#Lmb/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J)
increased incidence of tumors by chemical induction J:240961
increased metastatic potential J:240961
increased tumor growth/size J:240961
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Tg(Mt1-HGFSF)#Lmb/0

(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-HGFSF)#Lmb)
increased cutaneous melanoma incidence J:111992
increased incidence of tumors by chemical induction J:111992
increased metastatic potential J:111992
increased skin tumor incidence J:111992
increased tumor growth/size J:111992
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd
Tg(Tyr-NRAS*Q61K)1Bee/0

(FVB.Cg-Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee)
increased cutaneous melanoma incidence J:222847
increased incidence of tumors by UV-induction J:222847
Cdk4tm2.1Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ)
decreased tumor growth/size J:161780
increased adenocarcinoma incidence J:161780
Cdk4tm2.2Bbd/Cdk4tm2.1Bbd
Krastm1Bbd/Krastm2Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ)
decreased tumor growth/size J:161780
decreased tumor incidence J:161780
increased tumor incidence J:161780
Cdk4tm2.2Bbd/Cdk4tm2.2Bbd
Krastm1Bbd/Krastm1Bbd
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ)
decreased tumor incidence J:161780
Cdk5rap2an/Cdk5rap2an
(Not Specified)
increased ovary adenoma incidence J:15165
Cdk5rap2an/Cdk5rap2an
Tyrp1B-lt/Tyrp1B-lt

(WBB6F1)
increased histiocytic sarcoma incidence J:102334
Cdk6tm1Bbd/Cdk6tm1Bbd
Krastm1Bbd/Kras+
Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd

(involves: 129S1/Sv * 129X1/SvJ)
increased adenoma incidence J:161780
increased lung non-small cell carcinoma incidence J:161780
Cdk6tm1Phin/Cdk6+
Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S4/SvJae)
increased T cell derived lymphoma incidence J:144975
Cdk6tm1Phin/Cdk6tm1Phin
Tg(Lck-Akt1*E40K)E-3Pnt/0

(involves: 129S4/SvJae)
neoplasm J:144975
Cdk11bGt(XG836)Byg/Cdk11bGt(XG836)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
increased skin papilloma incidence J:125424
Cdkn1atm1(HBsAg)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
increased hepatocellular carcinoma incidence J:88078
Cdkn1atm1(HBsAg)Xya/Cdkn1atm1(HBsAg)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
increased hepatocellular carcinoma incidence J:88078
Cdkn1atm1Led/Cdkn1atm1Led
(NIH.Cg-Cdkn1atm1Led)
abnormal tumor incidence J:87536
decreased lymphoma incidence J:87536
Cdkn1atm1Led/Cdkn1atm1Led
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Tg(Upk2-cre)6Xrw/0

(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N)
increased urinary bladder carcinoma incidence J:234236
Cdkn1atm1Led/Cdkn1atm1Led
Tg(Upk2-cre)6Xrw/0

(involves: 129S6/SvEvTac * FVB/N)
neoplasm J:234236
Cdkn1atm1Led/Cdkn1atm1Led
Wrntm1Led/Wrntm1Led

(either: (involves: 129S6/SvEvTac) or (involves: 129S6/SvEvTac * NIH Black Swiss))
increased tumor incidence J:68488
Cdkn1atm1Tyj/Cdkn1a+
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J)
increased incidence of tumors by ionizing radiation induction J:83967
increased malignant tumor incidence J:83967
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
decreased incidence of tumors by ionizing radiation induction J:70894
increased B cell derived lymphoma incidence J:70894
increased carcinoma incidence J:70894
increased hemangiosarcoma incidence J:70894
increased histiocytic sarcoma incidence J:70894
increased incidence of tumors by chemical induction J:80271
increased Leydig cell tumor incidence J:70894
increased lung carcinoma incidence J:70894
increased sebaceous gland adenoma incidence J:70894
increased skin tumor incidence J:70894
increased T cell derived lymphoma incidence J:70894
increased tumor incidence J:70894
increased urinary system tumor incidence J:70894
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129/Sv * 129S2/SvPas * C57BL/6)
increased squamous cell carcinoma incidence J:72780
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S1/SvImJ * 129S2/SvPas * C57BL/6J)
increased incidence of tumors by ionizing radiation induction J:83967
increased malignant tumor incidence J:83967
increased metastatic potential J:83967
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Cdkn2atm1Rdp/Cdkn2atm1Rdp

(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL)
increased squamous cell carcinoma incidence J:72780
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Csnk1a1tm1.1Ybn/Csnk1a1tm1.1Ybn
Tg(Vil1-cre/ERT2)23Syr/0

(involves: 129 * C57BL/6 * CD-1 * DBA/2)
increased carcinoma incidence J:204886
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Fahtm1Mgo/Fahtm1Mgo

(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
increased hepatocellular carcinoma incidence J:138701
increased renal carcinoma incidence J:138701
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Ptentm1Hwu/Ptentm1Hwu
Tg(Fabp1-cre)1Jig/0

(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
increased urinary bladder carcinoma incidence J:106662
Cdkn1atm1Tyj/Cdkn1atm1Tyj
Tg(MMTV-vHaras)SH1Led/0

(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
decreased tumor latency J:66183
increased mammary adenocarcinoma incidence J:66183
increased salivary adenocarcinoma incidence J:66183
increased tumor incidence J:66183
Cdkn1atm2(HBx)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
increased hepatocellular carcinoma incidence J:88078
Cdkn1atm2(HBx)Xya/Cdkn1atm2(HBx)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
increased hepatocellular carcinoma incidence J:88078
Cdkn1btm1Ako/Cdkn1b+
KitW-v/KitW-v

(involves: 129S1/Sv * C57BL/6J)
increased ovary adenoma incidence J:236161
increased ovary tumor incidence J:236161
Cdkn1btm1Ako/Cdkn1b+
Ptentm2.1Ppp/Ptentm2.1Ppp
Tg(TPO-cre)1Shk/0

(129S1.Cg-Cdkn1btm1Ako Ptentm2.1Ppp Tg(TPO-cre)1Shk)
increased thyroid adenoma incidence J:165293
increased thyroid carcinoma incidence J:165293
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv * C57BL/6)
increased pituitary gland tumor incidence J:50053
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv)
increased lung adenocarcinoma incidence J:120835
increased ovary tumor incidence J:236161
Cdkn1btm1Ako/Cdkn1btm1Ako
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi

(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
increased carcinoma incidence J:50053
increased pituitary adenoma incidence J:50053
Cdkn1btm1Ako/Cdkn1btm1Ako
KitW-v/KitW-v

(involves: 129S1/Sv * C57BL/6J)
increased ovary adenoma incidence J:236161
increased ovary tumor incidence J:236161
Cdkn1btm1Ako/Cdkn1btm1Ako
Men1tm1.1Ctre/Men1+

(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
increased adrenal gland tumor incidence J:120835
increased lung adenoma incidence J:120835
increased pancreas tumor incidence J:120835
increased parathyroid gland tumor incidence J:120835
increased pituitary gland tumor incidence J:120835
increased testis tumor incidence J:120835
increased thyroid tumor incidence J:120835
increased tumor incidence J:120835
Cdkn1btm1Kin/Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
increased pituitary adenoma incidence J:33402
Cdkn1btm1Mlf/Cdkn1b+
(involves: 129S4/SvJaeSor)
increased incidence of tumors by chemical induction J:103819
Cdkn1btm1Mlf/Cdkn1b+
Crebbptm1Jvd/Crebbptm1Jvd
Tg(MMTV-cre)4Mam/0

(involves: 129 * C57BL/6 * CBA * FVB)
increased T cell derived lymphoma incidence J:88323
Cdkn1btm1Mlf/Cdkn1b+
Ptch1tm1Mps/Ptch1+

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
increased gastrointestinal tumor incidence J:205254
increased hemangiosarcoma incidence J:205254
increased lymphoma incidence J:205254
increased medulloblastoma incidence J:205254
increased rhabdomyosarcoma incidence J:205254
increased tumor incidence J:205254
Cdkn1btm1Mlf/Cdkn1b+
Tg(TG-TPR/NTRK1)#Rstn/0

(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
increased pituitary adenoma incidence J:33400
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor)
increased incidence of tumors by chemical induction J:103819
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa

(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
increased prostate intraepithelial neoplasia incidence J:89571
preneoplasia J:89571
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Ptch1tm1Mps/Ptch1+

(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
increased gastrointestinal tumor incidence J:205254
increased hemangiosarcoma incidence J:205254
increased lymphoma incidence J:205254
increased medulloblastoma incidence J:205254
increased rhabdomyosarcoma incidence J:205254
increased tumor incidence J:205254
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Tg(MMTV-vHaras)SH1Led/0

(involves: 129S4/SvJaeSor * C57BL/6J * CD-1)
increased tumor growth/size J:80271
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Tg(TG-TPR/NTRK1)#Rstn/0

(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
increased thyroid carcinoma incidence J:210015
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd

(involves: C3H * C57BL/6J * NIH)
increased sarcoma incidence J:87536
increased T cell derived lymphoma incidence J:87536
increased tumor incidence J:87536
Cdkn1btm1Mlf/Cdkn1btm1Mlf
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
increased sarcoma incidence J:87536
increased T cell derived lymphoma incidence J:87536
increased tumor incidence J:87536
Cdkn1btm2Jro/Cdkn1btm2Jro
(involves: 129S4/SvJaeSor * C57BL/6)
decreased incidence of tumors by chemical induction J:103819
Cdkn1btm2Kin/Cdkn1btm2Kin
Rassf5tm1Kina/Rassf5tm1Kina

(involves: C57BL/6 * CBA)
neoplasm J:168749
Cdkn1btm2Mlf/Cdkn1btm2Mlf
Tg(Pomc1-cre)1Mlf/0

(involves: 129S4/SvJaeSor)
increased pituitary gland tumor incidence J:107588
Cdkn1btm3Mlf/Cdkn1btm3Mlf
(involves: 129S4/SvJaeSor)
increased pituitary gland tumor incidence J:107588
Cdkn1btm3Mlf/Cdkn1btm3Mlf
Tg(Pomc1-cre)1Mlf/0

(involves: 129S4/SvJaeSor)
decreased tumor incidence J:107588
Cdkn2aem1Cjs/Cdkn2aem1Cjs
(B6.Cg-Cdkn2aem1Cjs)
increased acute lymphoblastic leukemia incidence J:244260
Cdkn2aem2Cjs/Cdkn2aem2Cjs
(C57BL/6-Cdkn2aem2Cjs)
neoplasm J:244260
Cdkn2aPctr1-DBA/2N/?
(involves: BALB/cAnPt * DBA/2N)
decreased tumor incidence J:16958
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
(involves: 129S1/Sv * C57BL/6)
increased gastrointestinal stromal tumor incidence J:87339
increased hemangiosarcoma incidence J:87339
increased histiocytic sarcoma incidence J:87339
increased incidence of tumors by ionizing radiation induction J:87339
increased lymphoma incidence J:87339
increased sarcoma incidence J:87339
increased tumor incidence J:87339
Cdkn2atm1.1Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
increased mesothelioma incidence J:132943
increased metastatic potential J:132943
increased rhabdomyosarcoma incidence J:132943
increased tumor incidence J:132943
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
(involves: 129P2/OlaHsd * FVB/N)
decreased incidence of tumors by chemical induction J:125189
neoplasm J:71393
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Cdkn2btm2Brn/Cdkn2btm2Brn

(involves: 129P2/OlaHsd * FVB/N)
increased incidence of tumors by chemical induction J:125189
increased skin tumor incidence J:125189
neoplasm J:125189
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth

(involves: 129P2/OlaHsd * FVB/N)
increased liver tumor incidence J:131179
increased meningioma incidence J:131179
increased osteoma incidence J:131179
osseous metaplasia J:131179
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Ptgdstm1.1(cre)Gvn/Ptgds+

(involves: 129P2/OlaHsd * FVB/N)
increased meningioma incidence J:173718
neoplasm J:173718
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Nf2tm2Gth/Nf2tm2Gth
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
increased mesothelioma incidence J:132943
increased rhabdomyosarcoma incidence J:132943
increased Schwannoma incidence J:132943
increased tumor incidence J:132943
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
increased mesothelioma incidence J:132943
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N)
increased adenocarcinoma incidence J:198619
increased pancreas adenoma incidence J:198619
increased pancreas tumor incidence J:198619
increased pancreatic intraepithelial neoplasia incidence J:198619
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJaeSor * C57BL/6J * FVB/N)
neoplasm J:198619
Cdkn2atm1Cjs/Cdkn2a+
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
increased carcinoma incidence J:93298
increased incidence of tumors by chemical induction J:93298
increased papilloma incidence J:93298
Cdkn2atm1Cjs/Cdkn2a+
Kat5tm1Jwl/Kat5+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
decreased tumor latency J:125164
Cdkn2atm1Cjs/Cdkn2a+
Ppm1dtm1Lad/Ppm1dtm1Lad
Tg(IghMyc)22Bri/0

(involves: 129 * C57BL * FVB/N * SJL)
decreased tumor incidence J:120284
Cdkn2atm1Cjs/Cdkn2a+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0

(involves: 129X1/SvJ * FVB)
increased rhabdomyosarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
increased acute lymphoblastic leukemia incidence J:244260
increased carcinoma incidence J:44427
increased fibrohistocytoma incidence J:44427
increased fibrosarcoma incidence J:44427
increased incidence of tumors by chemical induction J:44427
increased incidence of tumors by ionizing radiation induction J:44427
increased lymphoma incidence J:44427
increased T cell derived lymphoma incidence J:44427
increased tumor incidence J:44427
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
increased carcinoma incidence J:93298
increased incidence of tumors by chemical induction J:93298
increased metastatic potential J:93298
increased papilloma incidence J:93298
increased squamous cell carcinoma incidence J:93298
increased tumor growth/size J:93298
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7+
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0

(involves: 129S2/SvPas * 129X1/SvJ * FVB)
increased rhabdomyosarcoma incidence J:237183
increased sarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Pax7tm1Pgr/Pax7tm1Pgr
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0

(involves: 129S2/SvPas * 129X1/SvJ * FVB)
increased rhabdomyosarcoma incidence J:237183
increased sarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)68Dla/0

(involves: 129X1/SvJ * FVB/N)
increased leukemia incidence J:99991
increased lung adenocarcinoma incidence J:99991
increased lymphoma incidence J:99991
increased osteosarcoma incidence J:99991
increased sarcoma incidence J:99991
increased tumor incidence J:99991
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Sclt1Tg(CAG-sb10)1Dla/0
TgTn(sb-T2/Onc)76Dla/0

(involves: 129X1/SvJ * FVB/N)
increased leukemia incidence J:99991
increased lung adenocarcinoma incidence J:99991
increased lymphoma incidence J:99991
increased osteosarcoma incidence J:99991
increased sarcoma incidence J:99991
increased tumor incidence J:99991
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tacstd2tm1Lsm/Tacstd2tm1Lsm

(involves: 129X1/SvJ * C57BL/6)
increased carcinoma incidence J:182647
increased skin squamous cell carcinoma incidence J:182647
increased spindle cell carcinoma incidence J:182647
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(CKMM-tTA)A3Rhvh/0
Tg(tetO-Hgf,-EGFP)24Tcre/0

(involves: 129X1/SvJ * FVB)
increased rhabdomyosarcoma incidence J:237183
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(GFAP-TVA)5Hev/0

(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB/N)
increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Tg(NES-TVA)J12Ech/0

(involves: 129X1/SvJ * C57BL/6 * FVB/N)
increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
Cdkn2atm1Cjs/Cdkn2atm1Cjs
Trp53tm1Brd/Trp53tm1Brd

(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * NIH/OlaHsd)
abnormal tumor incidence J:93298
increased carcinoma incidence J:93298
increased tumor growth/size J:93298
Cdkn2atm1Nesh/Cdkn2atm1Nesh
(involves: 129S6/SvEvTac * FVB/N)
increased incidence of tumors by chemical induction J:88365
increased lung carcinoma incidence J:88365
increased osteosarcoma incidence J:88365
increased sarcoma incidence J:88365
increased small lymphocytic lymphoma incidence J:88365
increased tumor incidence J:88365
Cdkn2atm1Nesh/Cdkn2atm1Nesh
X/Tg(Tyr-HRAS)60Lc

(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB)
increased melanoma incidence J:85075
Cdkn2atm1Rdp/Cdkn2a+
Nf1tm1Tyj/Nf1+

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased neurofibrosarcoma incidence J:131914
Cdkn2atm1Rdp/Cdkn2a+
Terctm1Rdp/Terctm1Rdp

(involves: 129/Sv * C57BL/6J * SJL)
increased lymphoma incidence J:120065
increased sarcoma incidence J:120065
increased tumor incidence J:120065
Cdkn2atm1Rdp/Cdkn2a+
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0
Tg(Pdx1-cre)6Tuv/0
Tg(tetO-MYC)36Bop/0

(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
increased metastatic potential J:197052
increased pancreas tumor incidence J:197052
increased pancreatic ductal adenocarcinoma incidence J:197052
Cdkn2atm1Rdp/Cdkn2a+
Tg(NES-TVA)J12Ech/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
increased glioma incidence J:52161
Cdkn2atm1Rdp/Cdkn2a+
Tg(S100b-v-erbB)4496Waw/0

(involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL)
increased glioma incidence J:82649
Cdkn2atm1Rdp/Cdkn2a+
X/Tg(Tyr-HRAS)60Lc

(involves: 129/Sv * C57BL/6J * CBA/J * FVB/N * SJL)
increased incidence of tumors by UV-induction J:140820
increased intraocular melanoma incidence J:140820
Cdkn2atm1Rdp/Cdkn2a+
Tg(Tyr-NRAS*Q61K)1Bee/?

(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
increased cutaneous melanoma incidence J:98545
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * SJL)
increased B cell derived lymphoma incidence J:53805
increased cutaneous melanoma incidence J:98545
increased fibrosarcoma incidence J:53805
increased hemangiosarcoma incidence J:53805
increased sarcoma incidence J:53805
increased tumor incidence J:53805
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
increased lymphoma incidence J:88365
increased sarcoma incidence J:88365
increased tumor incidence J:88365
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
increased squamous cell carcinoma incidence J:72780
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
increased brain tumor incidence J:163931
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char
Ptentm1Hwu/Ptentm1Hwu

(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu

(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char
Ptentm1Hwu/Ptentm1Hwu

(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
increased glioblastoma incidence J:146494
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129/Sv * C57BL/6J * FVB * SJL)
increased melanoma incidence J:155731
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+
Pdgfratm12Sor/Pdgfra+

(involves: 129 * C57BL/6J * SJL)
increased fibrosarcoma incidence J:146617
increased sarcoma incidence J:146617
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Ptentm1Rdp/Ptentm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129/Sv * C57BL/6J * FVB * SJL)
increased melanoma incidence J:221902
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Krastm4Tyj/Kras+

(involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL)
increased lung adenocarcinoma incidence J:124682
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Mxi1tm1Rdp/Mxi1tm1Rdp

(involves: 129/Sv * C57BL/6J * SJL)
increased tumor incidence J:48236
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Nf1tm1Tyj/Nf1+

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased leukemia incidence J:131914
increased lymphoma incidence J:131914
increased neurofibrosarcoma incidence J:131914
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Ptentm1Rps/Ptentm1Rps
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129/Sv * 129S1/Sv * C57BL/6J * FVB/N * SJL)
increased melanoma incidence J:155731
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Rnf2tm1Mvi/Rnf2tm1Mvi
Tg(Mx1-cre)1Cgn/0

(involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL)
increased lymphoma incidence J:130397
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Sox10tm1Weg/Sox10+
Tg(Tyr-NRAS*Q61K)1Bee/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2 * SJL)
neoplasm J:193443
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Terctm1Rdp/Terctm1Rdp

(involves: 129/Sv * C57BL/6J * SJL)
increased lymphoma incidence J:120065
increased sarcoma incidence J:120065
increased tumor incidence J:120065
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(GFAP-TVA)5Hev/0

(involves: 129/Sv * BALB/c * C57BL/6 * FVB/N * SJL)
increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(GFAP-TVA)10Ech/0

(involves: 129 * BALB/c * C57BL/6 * FVB/N * SJL)
increased glioma incidence J:52161
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Mt1-HGFSF)19Lmb/0

(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
increased melanoma incidence J:79704
increased rhabdomyosarcoma incidence J:79704
increased tumor incidence J:79704
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(NES-TVA)J12Ech/0

(involves: 129 * C57BL/6 * FVB/N * SJL)
increased glioma incidence J:52161
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(NES-TVA)J12Ech/0

(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
increased glioma incidence J:125535
increased oligodendroglioma incidence J:153220
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(S100b-v-erbB)4496Waw/0

(involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL)
decreased tumor latency J:82649
increased glioma incidence J:82649
increased oligodendroglioma incidence J:82649
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Kras2)12Hev/0

(involves: 129 * C57BL/6J * FVB/N * SJL)
increased lung adenocarcinoma incidence J:73468, J:166963
increased lung tumor incidence J:73468
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-BRAF*V600E)29Lc/0
Tg(Tyr-rtTA)37Lc/0

(involves: 129/Sv * C57BL/6J * SJL)
increased prostate gland adenocarcinoma incidence J:144358
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(tetO-Nras*Q61K)#Lc/0
Tg(Tyr-rtTA)37Lc/0

(FVB.Cg-Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc Tg(Tyr-rtTA)37Lc)
increased cutaneous melanoma incidence J:238049
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)470Fgh/0

(involves: 129/Sv * C57BL/6J * CBA * SJL)
increased melanoma incidence J:151455
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-BRAF*V600E)476Fgh/0

(involves: 129/Sv * C57BL/6J * CBA * SJL)
increased melanoma incidence J:151455
Cdkn2atm1Rdp/Cdkn2atm1Rdp
X/Tg(Tyr-HRAS)60Lc

(involves: 129/Sv * C57BL/6J * CBA/J * SJL)
decreased tumor growth/size J:164588
increased melanoma incidence J:164588
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/?

(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
increased cutaneous melanoma incidence J:98545
increased metastatic potential J:98545
Cdkn2atm1Rdp/Cdkn2atm1Rdp
Tg(Tyr-NRAS*Q61K)1Bee/0

(involves: 129/Sv * C57BL/6J * DBA/2 * SJL)
increased cutaneous melanoma incidence J:193443
Cdkn2atm1Sxs/Cdkn2atm1Sxs
(involves: 129/Sv * C57BL/6)
abnormal tumor incidence J:149526
Cdkn2atm2.1Brn/Cdkn2atm2.1Brn
(involves: 129P2/OlaHsd * FVB/N)
increased carcinoma incidence J:71393
increased incidence of tumors by chemical induction J:71393
increased lymphoma incidence J:71393
increased melanoma incidence J:71393
increased metastatic potential J:71393
increased sarcoma incidence J:71393
increased tumor incidence J:71393
Cdkn2atm2.1Nesh/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129S4/SvJae * C57BL/6 * FVB)
increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Tg(Tyr-cre/ERT2)13Bos/0

(B6J.Cg-Cdkn2atm2.1Nesh Krastm4Tyj Tg(Tyr-cre/ERT2)13Bos)
increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
increased melanoma incidence J:164588
increased spindle cell carcinoma incidence J:164588
increased tumor growth/size J:164588
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Stk11tm1.1Rdp/Stk11tm1.1Rdp
Tg(Tyr-cre/ERT2)13Bos/0

(B6J.Cg-Nrastm1.1Nesh Cdkn2atm2.1Nesh Stk11tm1.1Rdp Tg(Tyr-cre/ERT2)13Bos)
increased cutaneous melanoma incidence J:220627
increased metastatic potential J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1.1Nesh/Nrastm1.1Nesh
Tg(Tyr-cre/ERT2)13Bos/0

(B6J.Cg-Nrastm1.1Nesh Cdkn2atm2.1Nesh Tg(Tyr-cre/ERT2)13Bos)
increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Nrastm1Tyj/Nrastm1Tyj
Tg(Tyr-cre/ERT2)13Bos/0

(B6J.Cg-Nrastm1Tyj Cdkn2atm2.1Nesh Tg(Tyr-cre/ERT2)13Bos)
increased cutaneous melanoma incidence J:220627
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh
Trp53tm1Brn/Trp53tm1Brn
Tg(Tyr-cre/ERT2)13Bos/0

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
increased melanoma incidence J:164588
Cdkn2atm2.1Rdp/Cdkn2a+
(involves: 129S6/SvEvTac * FVB/N)
increased tumor incidence J:71394
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
increased incidence of tumors by chemical induction J:71394, J:88365
increased lymphoma incidence J:88365
increased osteosarcoma incidence J:88365
increased sarcoma incidence J:88365
increased small lymphocytic lymphoma incidence J:88365
increased tumor incidence J:71394, J:88365
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
increased lung adenocarcinoma incidence J:124682
increased metastatic potential J:124682
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)6Tuv/0

(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
increased adenocarcinoma incidence J:198619
increased pancreas adenoma incidence J:198619
increased pancreas tumor incidence J:198619
increased pancreatic intraepithelial neoplasia incidence J:198619
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Pdx1-cre)89.1Dam/0

(involves: 129 * C57BL/6 * CBA * FVB/N)
increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Nf1tm1Tyj/Nf1+

(involves: 129S2/SvPas * 129S6/SvEvTac)
increased lymphoma incidence J:131914
neoplasm J:131914
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(GFAP-TVA)5Hev/0

(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N)
increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Tg(NES-TVA)J12Ech/0

(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
increased glioma incidence J:125535
increased oligodendroglioma incidence J:125535
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
X/Tg(Tyr-HRAS)60Lc

(involves: 129S6/SvEvTac * C57BL/6J * CBA/J * FVB)
increased melanoma incidence J:85075
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
increased lung tumor incidence J:124682
Cdkn2atm2Brn/Cdkn2a+
Nf2tm2Gth/Nf2tm2Gth

(involves: 129P2/OlaHsd)
increased leukemia incidence J:132943
increased tumor incidence J:132943
increased uterus leiomyoma incidence J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2+

(involves: 129P2/OlaHsd)
increased leukemia incidence J:132943
increased tumor incidence J:132943
increased uterus leiomyoma incidence J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Nf2tm2Gth/Nf2tm2Gth

(involves: 129P2/OlaHsd)
increased leukemia incidence J:132943
increased rhabdomyosarcoma incidence J:132943
increased tumor incidence J:132943
increased uterus leiomyoma incidence J:132943
Cdkn2atm2Brn/Cdkn2atm2Brn
Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0

(involves: C57BL/6 * FVB/N)
increased classified tumor incidence J:107175
increased cutaneous melanoma incidence J:107175
increased neurofibrosarcoma incidence J:107175
Cdkn2atm4Cjs/Cdkn2atm4Cjs
(involves: 129S1/Sv * C57BL/6)
neoplasm J:147752
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
increased tumor incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
increased stomach tumor incidence J:116130
increased tumor incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2a+
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased metastatic potential J:108298
increased pancreas tumor incidence J:108298
increased pancreatic ductal adenocarcinoma incidence J:108298
Cdkn2atm4Rdp/Cdkn2a+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
neoplasm J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+

(involves: 129S4/SvJae)
increased lung adenocarcinoma incidence J:195492
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+

(involves: 129S4/SvJae * C57BL/6)
increased sarcoma incidence J:125101
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Ptf1atm1.1(cre)Cvw/Ptf1a+

(involves: 129 * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Smad4tm1Rdp/Smad4tm1Rdp
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased pancreatic ductal adenocarcinoma incidence J:116130
increased stomach tumor incidence J:116130
increased tumor incidence J:116130
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
increased malignant tumor incidence J:87196
increased metastatic potential J:87196, J:108298
increased pancreas tumor incidence J:87196, J:108298
increased pancreatic ductal adenocarcinoma incidence J:116130, J:87196, J:108298
increased pancreatic intraepithelial neoplasia incidence J:87196
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Kras+
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * CBA)
increased pancreatic ductal adenocarcinoma incidence J:187012
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Krastm4Tyj/Krastm4Tyj
Tg(Pdx1-cre)89.1Dam/0

(involves: 129S4/SvJae * C57BL/6 * DBA/2)
increased pancreas tumor incidence J:151781
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Myf6tm1(cre)Mrc/Myf6+
Pax3tm1Mrc/Pax3tm1Mrc

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased rhabdomyosarcoma incidence J:93444
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Nf1tm1Par/Nf1tm1Par

(involves: 129S1/Sv * 129X1/SvJ)
increased neurofibrosarcoma incidence J:234760
increased rhabdomyosarcoma incidence J:234760
increased sarcoma incidence J:234760
Cdkn2atm4Rdp/Cdkn2atm4Rdp
Tg(Pdx1-cre)89.1Dam/0

(involves: C57BL/6 * CBA * FVB/N)
neoplasm J:87196
Cdkn2btm1Bbd/Cdkn2btm1Bbd
(involves: 129S1/Sv * C57BL/6)
increased adenocarcinoma incidence J:63299
increased sarcoma incidence J:63299
increased tumor incidence J:63299
Cdkn2btm1Bbd/Cdkn2btm1Bbd
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd

(involves: 129S1/Sv * C57BL/6)
increased lymphoma incidence J:63299
increased pituitary adenoma incidence J:63299
increased sarcoma incidence J:63299
increased testis tumor incidence J:63299
increased tumor incidence J:63299
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53+

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2c+
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
increased B cell derived lymphoma incidence J:63299
increased hemangiosarcoma incidence J:63299
increased pheochromocytoma incidence J:63299
increased pituitary adenoma incidence J:63299
increased renal carcinoma incidence J:63299
increased T cell derived lymphoma incidence J:63299
increased testis tumor incidence J:63299
neoplasm J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Cdkn2dtm1Maro/Cdkn2dtm1Maro

(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
increased pheochromocytoma incidence J:68829
increased pituitary adenoma incidence J:68829
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Ptch1tm1Mps/Ptch1+

(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Ptch1tm1Mps/Ptch1+

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased medulloblastoma incidence J:205254
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Brn/Trp53tm1Tyj
Tg(Nes-cre)1Kln/0

(involves: 129P2/OlaHsd * 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
increased medulloblastoma incidence J:102702
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
increased medulloblastoma incidence J:102702
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
increased pituitary adenoma incidence J:50053
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(B6.129-Cdkn2ctm1Yxi)
increased lung adenocarcinoma incidence J:120835
increased lung adenoma incidence J:120835
increased lung tumor incidence J:120835
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi)
increased mammary gland tumor incidence J:198018
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
Men1tm1.1Ctre/Men1+

(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
decreased tumor latency J:120835
increased adenocarcinoma incidence J:120835
increased adrenal gland tumor incidence J:120835
increased Leydig cell tumor incidence J:120835
increased lung adenocarcinoma incidence J:120835
increased lung adenoma incidence J:120835
increased lung tumor incidence J:120835
increased pancreas tumor incidence J:120835
increased parathyroid gland tumor incidence J:120835
increased testis tumor incidence J:120835
increased thyroid tumor incidence J:120835
Cdsntm1.1Ics/Cdsntm1.1Ics
Tg(KRT14-cre)1Ipc/0

(involves: 129S2/SvPas * C57BL/6 * SJL)
increased skin papilloma incidence J:153292
Cdx2tm1Fbe/Cdx2+
(involves: 129S1/Sv * C57BL/6J)
increased colon adenoma incidence J:38772
increased intestinal adenoma incidence J:38772
Cdx2tm1Mmt/Cdx2+
(involves: 129X1/SvJ * C57BL/6)
increased colon hamartoma incidence J:47050
Ceacam1tm2Bcn/Ceacam1tm2Bcn
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased incidence of tumors by chemical induction J:115838
Cebpatm1Gonz/Cebpatm1Gonz
Tg(KRT5-cre)5132Jlj/0

(involves: 129X1/SvJ * C57BL/6 * DBA/2J)
increased skin papilloma incidence J:123139
increased skin tumor incidence J:123139
increased squamous cell carcinoma incidence J:123139
increased tumor growth/size J:123139
Cebpatm1Timc/Cebpatm1Timc
(Not Specified)
increased incidence of tumors by chemical induction J:163725
Cebpatm8.1Nerl/Cebpatm8.1Nerl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
increased leukemia incidence J:136134
Cebpbtm1Es/Cebpbtm1Es
Tg(KRT5-cre)5132Jlj/?

(involves: 129S1 * C57BL/6J * DBA/2J)
decreased incidence of tumors by chemical induction J:107334
Cebpbtm1Pfj/Cebpb+
(B6.Cg-Cebpbtm1Pfj)
decreased incidence of tumors by chemical induction J:73558
Cebpbtm1Pfj/Cebpbtm1Pfj
(B6.Cg-Cebpbtm1Pfj)
decreased incidence of induced tumors J:73558
decreased incidence of tumors by chemical induction J:73558
Cebpbtm1Pfj/Cebpbtm1Pfj
Tg(Hba-x-v-Ha-ras)TG.ACLed/0

(involves: C57BL/6)
decreased incidence of tumors by chemical induction J:73558
decreased tumor growth/size J:73558
Cep57em1Jvd/Cep57+
(involves: 129 * C57BL/6)
increased incidence of tumors by chemical induction J:264300
increased lung adenoma incidence J:264300
increased tumor incidence J:264300
Cep57em2Jvd/Cep57+
(involves: FVB/N)
increased lung adenoma incidence J:264300
increased tumor incidence J:264300
Cers2Gt(S16-4B1)Sor/Cers2Gt(S16-4B1)Sor
(involves: 129S4/SvJaeSor * C57BL/6)
increased hepatocellular carcinoma incidence J:156841
increased liver tumor incidence J:156841
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
increased lymphoma incidence J:146176
increased T cell derived lymphoma incidence J:146176
Chek1tm1Sje/Chek1+
(Not Specified)
neoplasm J:62919
Chek1tm1Sje/Chek1+
Tg(Wnt1)1Hev/0

(Not Specified)
increased mammary adenocarcinoma incidence J:62919
Chek1tm2.1Sje/Chek1+
Tg(MMTV-cre)#Mam/0

(involves: FVB)
neoplasm J:162126
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
abnormal tumor morphology J:162126
abnormal tumor vascularization J:162126
increased mammary adenocarcinoma incidence J:162126
increased mammary gland tumor incidence J:162126
Chek1tm2.1Sje/Chek1+
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
decreased tumor incidence J:162126
increased mammary gland tumor incidence J:162126
Chek1tm2.1Sje/Chek1tm2.1Sje
Tg(MMTV-cre)#Mam/0

(involves: FVB)
neoplasm J:162126
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53+
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
increased mammary gland tumor incidence J:162126
Chek1tm2.1Sje/Chek1tm2.1Sje
Trp53tm1Brn/Trp53tm1Brn
Tg(MMTV-cre)#Mam/0

(involves: 129P2/OlaHsd * FVB)
abnormal tumor morphology J:162126
decreased tumor incidence J:162126
Chek2tm1Mak/Chek2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6)
increased incidence of tumors by chemical induction J:78491
Chek2tm1Mak/Chek2tm1Mak
Rad50tm2Jpt/Rad50tm2Jpt

(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
increased lymphoma incidence J:103922
Chfrtm1Jc/Chfr+
(involves: 129S/SvEv * C57BL/6)
increased incidence of tumors by chemical induction J:97428
increased lymphoma incidence J:97428
increased tumor incidence J:97428
Chfrtm1Jc/Chfrtm1Jc
(involves: 129S/SvEv * C57BL/6)
increased incidence of tumors by chemical induction J:97428
increased lymphoma incidence J:97428
increased tumor incidence J:97428
Chordc1tm1Mbra/Chordc1+
(Not Specified)
increased incidence of tumors by chemical induction J:159109
Chordc1tm1Mbra/Chordc1+
(involves: 129 * C57BL/6)
increased chronic myelocytic leukemia incidence J:222040
Chuktm1Yhu/Chuktm1Yhu
Tg(Krt1-5-cre/ERT)1Ipc/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased skin tumor incidence J:141162
Chuktm1Yhu/Chuktm1Yhu
Tg(Krt1-15-cre/PGR)22Cot/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
increased carcinoma incidence J:141162
increased skin papilloma incidence J:141162
increased skin tumor incidence J:141162
Chuktm1Yhu/Chuktm1Yhu
Tg(MMTV-cre)4Mam/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)
increased skin tumor incidence J:141162
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased lung tumor incidence J:197037
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
increased skin squamous cell carcinoma incidence J:197037
Chuktm2Yhu/Chuktm2Yhu
Tg(KRT5-CHUK)#Yhu/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
neoplasm J:197037
Chuktm2Yhu/Chuktm2Yhu
Tg(Lor-CHUK)8Yhu/0

(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
increased lung squamous cell carcinoma incidence J:197037
increased lung tumor incidence J:197037
Chuktm2Yhu/Chuktm2Yhu
Tg(Lor-CHUK)8Yhu/0

(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
increased squamous cell carcinoma incidence J:197037
Ciz1tm1.1Homy/Ciz1tm1.1Homy
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
increased tumor incidence following infection J:198470
Cks1btm1Sir/Cks1b+
Tg(IghMyc)22Bri/?

(involves: C57BL * C57BL/6 * SJL)
increased lymphoma incidence J:121564
Cks1btm1Sir/Cks1btm1Sir
Tg(IghMyc)22Bri/?

(involves: C57BL * C57BL/6 * SJL)
decreased metastatic potential J:121564
increased lymphoma incidence J:121564
Clp1tm1.1Pngr/Clp1tm1.1Pngr
Trp53tm1Tyj/Trp53tm1Tyj

(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J)
increased tumor incidence J:196364
Cmiptm1a(EUCOMM)Wtsi/Cmiptm1a(EUCOMM)Wtsi
(C57BL/6N-Cmiptm1a(EUCOMM)Wtsi/Wtsi)
embryo tumor J:239583
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
increased lung adenocarcinoma incidence J:235747
Col1a1tm1(CAG-Ezh2*)Meln/Col1a1+
Ighg1tm1(cre)Cgn/Ighg1+

(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
neoplasm J:199122
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp
Tg(Mx1-cre)1Cgn/0

(Not Specified)
increased leukemia incidence J:199366
increased T cell derived lymphoma incidence J:199366
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0

(involves: 129 * C57BL/6)
altered tumor pathology J:166724
increased lung carcinoma incidence J:166724
increased lung tumor incidence J:166724
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased sarcoma incidence J:194505
tumor regression J:194505
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
Tg(CAG-cat-lacZ)11Miya/0
H2az2Tg(Wnt1-cre)11Rth/0

(involves: 129S4/SvJae * C57BL/6 * CBA/J * DBA/2)
increased sarcoma incidence J:194505
Col1a1tm1(tetO-EWSR1/ATF1)Yasu/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sortm1(EYFP)Cos
Tg(Mpz-cre)94Imeg/0

(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
increased sarcoma incidence J:194505
Col1a1tm1(tetO-Fos)Wag/Col1a1+
Tg(KRT5-rtTA)T2D6Sgkd/0

(involves: 129S4/SvJae * C57BL/6 * FVB/N)
increased incidence of tumors by chemical induction J:201145
increased papilloma incidence J:201145
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(KRT14-cre)1Amc/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
increased skin squamous cell carcinoma incidence J:171057
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Pbsn-cre)4Prb/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
increased prostate gland adenocarcinoma incidence J:222916
increased prostate gland tumor incidence J:222916
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Flt3tm1.1Dosm/Flt3tm1.1Dosm
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?

(involves: 129 * C57BL/6)
increased leukemia incidence J:210097
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp
Gt(ROSA)26Sortm1(rtTA*M2)Jae/?

(involves: 129S4/SvJae * C57BL/6)
increased leukemia incidence J:210097
neoplasm J:210097
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Foxd1tm1(GFP/cre)Amc/Foxd1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
neoplasm J:211179
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Tg(Six2-EGFP/cre)1Amc/0

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CD-1)
neoplasm J:211179
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
Wt1tm2(cre/ERT2)Wtp/Wt1+

(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
increased kidney tumor incidence J:211179
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased skin tumor incidence J:98920
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased leukemia incidence J:171191
increased lymphoma incidence J:171191
increased T cell derived lymphoma incidence J:171191
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
increased lung tumor incidence J:214230
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
increased lung adenocarcinoma incidence J:214230
increased lung tumor incidence J:214230
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased leukemia incidence J:171191
increased lymphoma incidence J:171191
increased T cell derived lymphoma incidence J:171191
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+
Trp53tm1Brn/Trp53tm1Brn

(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
increased lung tumor incidence J:214230
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0

(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
increased lung adenoma incidence J:171191
increased tumor incidence J:171191
Col1a1tm6(tetO-MSI2)Jae/Col1a1+
Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+

(involves: 129S4/SvJae * C57BL/6)
increased leukemia incidence J:163322
Col4a2em1(IMPC)Wtsi/